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A B S T R A C T
Background
This is an updated version of a Cochrane review first published in Issue 3, 2006 (Perry 2006). The review represents one in a family of
four reviews focusing on the effectiveness of interventions in reducing drug use and criminal activity for offenders. This specific review
considers interventions for female drug-using offenders.
Objectives
To assess the effectiveness of interventions for female drug-using offenders in reducing criminal activity, or drug use, or both.
Search methods
We searched 14 electronic bibliographic databases up to May 2014 and five additional Website resources (between 2004 and November
2011). We contacted experts in the field for further information.
Selection criteria
We included randomised controlled trials (RCTs) designed to reduce, eliminate or prevent relapse of drug use or criminal activity in
female drug-using offenders. We also reported data on the cost and cost-effectiveness of interventions.
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration.
Main results
Nine trials with 1792 participants met the inclusion criteria. Trial quality and risks of bias varied across each study. We rated the
majority of studies as being at ’unclear’ risk of bias due to a lack of descriptive information. We divided the studies into different
categories for the purpose of meta-analyses: for any psychosocial treatments in comparison to treatment as usual we found low quality
evidence that there were no significant differences in arrest rates, (two studies; 489 participants; risk ratio (RR) 0.82, 95% confidence
interval (CI) 0.45 to 1.52) or drug use (one study; 77 participants; RR 0.65, 95% CI 0.20 to 2.12), but we found moderate quality
evidence that there was a significant reduction in reincarceration, (three studies; 630 participants; RR 0.46, 95% CI 0.34 to 0.64).
Pharmacological intervention using buprenorphine in comparison to a placebo did not significantly reduce self reported drug use (one
study; 36 participants; RR 0.58, 95% CI 0.25 to 1.35). No cost or cost-effectiveness evidence was reported in the studies.
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Authors’ conclusions
Three of the nine trials show a positive trend towards the use of any psychosocial treatment in comparison to treatment as usual
showing an overall significant reduction in subsequent reincarceration, but not arrest rates or drug use. Pharmacological interventions
in comparison to a placebo did not significantly reduce drug use and did not measure criminal activity. Four different treatment
comparisons showed varying results and were not combined due to differences in the intervention and comparison groups. The studies
overall showed a high degree of heterogeneity for types of comparisons and outcome measures assessed, which limited the possibility
to pool the data. Descriptions of treatment modalities are required to identify the important elements for treatment success in drug-
using female offenders. More trials are required to increase the precision of confidence with which we can draw conclusions about the
effectiveness of treatments for female drug-using offenders.
P L A I N L A N G U A G E S U M M A R Y
Interventions for female drug-using offenders
Background
Drug-using offenders naturally represent a socially excluded group where drug use is more prevalent than in the rest of the population.
A growing number of female offenders are being incarcerated for drug-related crimes. For this reason, it is important to investigate
what we know about what works for female offenders.
Study characteristics
The review authors searched scientific databases and Internet resources to identify randomised controlled trials (where participants are
allocated at random to one of two or more treatment groups) of interventions to reduce, eliminate, or prevent relapse of drug use or
criminal activity of female drug-using offenders. We included females of any age or ethnicity.
Key results
We identified nine trials of female drug-using offenders. Three studies included evaluations of therapeutic communities in comparison
to: i) an alternative sentencing option; ii) a substancemisuse educational cognitive skills programme; and iii) gender-responsive substance
abuse treatment for women in prison in comparison to standard therapeutic communities. Two studies evaluated community-based
management; one compared to standard probation and the other compared to standard parole supervision. Two studies evaluated
a cognitive behavioural programme versus treatment as usual and combined cognitive behavioural treatment and acceptance and
commitment therapy versus waiting list control. One study of a pharmacological intervention in comparison to a placebo or treatment
as usual. One study compared interpersonal psychotherapy to an attention matched control psychoeducational control.
Overall, the findings suggest that any psychosocial treatment in comparison to treatment as usual had an impact on reducing subsequent
reincarceration, but not rearrest or drug misuse. We found individual treatment interventions had differing effects. We identified
too few studies to evaluate whether the treatment setting (for example, court or community) had an impact on the success of such
programmes. Promising results highlight the use of psychosocial treatments in the reduction of reincarceration. No information is
provided on the cost and cost-effectiveness of these studies. In conclusion, high quality research is required to evaluate the effectiveness
of different treatment options for female drug-using offenders. Further information on the processes involved in the engagement of
women mandated to substance abuse programmes, together with evaluations of cost-effectiveness research, will enable policy makers
to make informed choices about commissioning the use of adapted programmes specifically targeted at female offenders.
Quality of the evidence
This review was limited by the lack of information reported in this group of trials and the quality of evidence was moderate to low.
The evidence is current to May 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any psychosocial intervention compared to treatment as usual: Drug use for female drug-using offenders
Patient or population: Patients with female drug-using offenders
Settings: Community/parole
Intervention: Any psychosocial intervention
Comparison: Treatment as usual: Drug use
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Treatment as usual:
Drug use
Any psychosocial inter-
vention
Self reported drug use
dichotomous
Follow-up: mean 9
months
Study population RR 0.65
(0.2 to 2.12)
77
(1 study)
⊕⊕©©
low1,2
158 per 1000 103 per 1000
(32 to 335)
Moderate
158 per 1000 103 per 1000
(32 to 335)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 7 of 9 items judged at unclear risk of bias.
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2 Only 1 study with 77 participants.
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B A C K G R O U N D
This review forms part of a family of four reviews providing a
close examination of what works in reducing drug use and crim-
inal activity in drug-using offenders. Overall, the four reviews
contain over 100 trials, generating a number of publications and
numerous comparisons (Perry 2013; Perry 2014b; Perry 2014a).
The four reviews represent a specific interest in pharmacological
interventions, non-pharmacological interventions, female offend-
ers and offenders with concurrent mental illness. All four reviews
stem from an updated Cochrane systematic review Perry 2006. In
this set of four reviews we consider not only the effectiveness of
interventions based on two key outcomes, but also analyse the im-
pact of setting and intervention type. We present here the revised
methodology for this updated review, focusing on the impact of
interventions for female drug-using offenders.
Description of the condition
Within the criminal justice system the number of women incar-
cerated for drug offences has significantly increased over the last
decade, with rates of incarceratedwomen rising faster than formen
(Bureau of Justice Statistics 2005). The latest UK Government
figures show that around 4.7% of the prison population in the
UK are women (Ministry of Justice 2012). In the United States
of America (USA), this figure is around 7% (Guerino 2011), with
around a quarter of all arrests being attributed to crimes commit-
ted by women (FBI 2011).
As with male offenders, drug use is an important issue for women.
A 2006 study of female prisoners found that 75.3%had used drugs
in the six months prior to prison entry, with 58% reporting daily
drug use in this period (Plugge 2006). Furthermore, the pattern
of drug use in female offenders has been recognised to differ from
that of the male population. Female offenders have been observed
to use cannabis less on average than men, but are more prone to
using so-called ’harder’ drugs such as heroin and amphetamines
(Forsythe 2009). Other gender differences have been noted in
variables thatmight have a bearing ondruguse anddrug treatment,
such as mental illness, raising children, employment prospects,
and patterns of offending (Forsythe 2009; Gelsthorpe 2007).
Early victimisation and severity of addiction are stronger predic-
tors of criminal activity and subsequentmental and physical health
problems for women than for men (Bloom 2004; Messina 2007).
Furthermore, women entering substance abuse treatment in prison
are at a substantial disadvantage compared with their male coun-
terparts (Messina 2007). Female offenders represent an under-re-
searched, vulnerable population with specific needs distinct from
their male counterparts (Corston 2007). Treatment for drug-in-
volved offenders is scarce, with estimates that fewer than 10% re-
ceive substance abuse treatment services (Taxman 2007).
Description of the intervention
There are many different treatments available for substance misuse
(e.g. detoxification, and therapeutic communities in the criminal
justice system. This review includes any intervention that was de-
signed to reduce, eliminate or prevent relapse to drug use or crim-
inal activity, or both. This resulted in the inclusion of a wide range
of treatment interventions focusing on: therapeutic community
and gender-responsive treatment programmes, community-based
management, cognitive skills and cognitive behavioural therapy,
pharmacological intervention (using buprenorphine), and inter-
personal psychotherapy. The evidence supporting the effectiveness
of these interventions differs and is dependent upon the quality of
the experimental evaluations employed to assess whether they are
successful in reducing drug use or criminal activity, or both.
Previous meta-analyses and systematic reviews of therapeutic com-
munity interventions, specifically with aftercare, have shownmod-
est effects in the reduction of recidivism and drug use (Mitchell
2012; Pearson 1999). gender-responsive treatment programmes
are designed to provide a secure environment for women offenders
to safely discuss histories of trauma, abuse, and addiction without
fear of judgment (Grella 2008).
Community-based management evolved traditionally to address
the needs of prisoner re-entry programmes covering employ-
ment, education, health, housing, and family support via assess-
ment and connecting clients with the appropriate services (Austin
1994). Case management in the USA has been applied in Treat-
ment Accountability for Safer Communities (TASC) programmes
(Marlowe 2003 a) and has shown initial effectiveness, but without
systematic evidence in support of the process. Contingency man-
agement, alongside voucher incentives have shown some modest
effects. To our knowledge, there has been no specific systematic
review evaluating the effectiveness of voucher incentive schemes
with drug-using offenders.
Cognitive-behavioural approaches, including selfmonitoring, goal
setting, self control training, interpersonal skills training, relapse
prevention, group work, lifestyle modification, and acceptance
commitment therapy, have shown signs of success with offenders
generally (Lipsey 2007), but the evidence excluded evaluations
focused specifically on drug-using offenders.
There have been a number of pharmacological reviews focus-
ing on the non-correctional population. Naltrexone mainte-
nance treatment for opioid dependence (Amato 2005; Lobmaier
2008; Minozzi 2011) and the efficacy of methadone maintenance
(Faggiano 2003; Marsch 1998; Mattick 2009) and buprenor-
phine maintenance (Mattick 2009) have been examined. Minozzi
2013 systematically reviewed the evidence on pharmacological
maintenance for non-correctional pregnant women and identi-
fied three small trials from which they were unable to draw firm
conclusions about the effectiveness of treatment. Other non-cor-
rectional reviews have investigated pharmacological interventions,
but not specifically for female offenders. These have included eval-
uations of naltrexone maintenance treatment for opioid depen-
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dence (Lobmaier 2008), the efficacy of methadone maintenance
including the management of opioid withdrawal (Amato 2013;
Faggiano 2003;Marsch 1998,Mattick 2009), and buprenorphine
maintenance and impact on dosage (Fareed 2012; Mattick 2009
). There is also recent guidance from the National Institute for
Health and Clinical Excellence (NICE) on the evidence-based use
of naltrexone, methadone, and buprenorphine for the manage-
ment of opioid dependence (NICE 2007a; NICE 2007b). How-
ever, none of these reviews focuses specifically on treatment out-
comes for female offenders.
Internationally, methadone maintenance has been the primary
choice for chronic opioid dependence in prisons and jails, in-
cluding those in the Netherlands, Australia, Spain and Canada,
and it is being increasingly implemented in the criminal jus-
tice setting (Moller 2007; Stallwitz 2007). The USA has not
generally endorsed the use of methadone treatment, and only
12% of correctional settings offer this option for incarcerated in-
mates (Fiscella 2004). Reasons for this lack of expansion suggest
that methadone amongst the public and criminal justice system
providers has been considered a substitute for another addiction.
In contrast, buprenorphine appears not to carry the same social
stigma associated with methadone treatment and has been used
in France, Austria and Puerto Rico (Catania 2003; Garcia 2007;
Reynaud-Maurupt 2005). Naltrexone treatment has shown some
promising findings, but associated problems surrounding high at-
trition and low medication compliance in the community and
high mortality rates (Gibson 2007; Minozzi 2011) pose concerns.
Trials conducted in the criminal justice setting are still lacking,
and continuity of care is considered crucial in the treatment of
drug-involved offenders who move between the prison and the
community.
Interpersonal psychotherapy has been used in the community with
proven effectiveness with non-criminal justice settings. Such stud-
ies have not found interpersonal psychotherapy to be superior to
other treatments, but few of these studies include female offenders
(Johnson 2012).
How the intervention might work
Therapeutic community programmes have been used in the USA
since the 1960s and, combined with work release programmes,
they attempt to rehabilitate offenders via a supportive environment
over a relatively long period which encompasses the transition be-
tween the prison and working within the community (Prendergast
2011). The ethos of therapeutic community interventions is to
focus on treatment of the whole self, such that residents are instru-
mental in running the therapeutic community (Mitchell 2012).
Gender-responsive treatment is a theoretically-based programme
which is used todevelop trauma-informed services. Based upon the
relational-cultural theory (Miller 1976), the programme is used to
describe women’s psychological development in relationships and
their connection to others.
Case management is a problematic term which describes a range
of diverse practices and supervision models spanning a number
of different services, including probation. The process is generally
used to co-ordinate and integrate all aspects of community su-
pervision, from the initial offender needs assessment, through to
programme delivery and the intended completion of the order or
sentencing requirement (Partridge 2004). Cognitive behavioural
approaches using programmes based on psychological theory have
been employed to try and help people address their offending be-
haviour, and generally have good support from the literature in
their reduction of recidivism (Andrews 1990; Lipsey 1998; Lipsey
2007).
Interpersonal psychotherapy addresses personal stress and life
changes. The emphasis is to engage with clients to develop their
network of social and peer support. A lack of support has been
shown to associate with dropping out of addiction treatment and
failure to maintain abstinence (Dobkin 2002; Holahan 2004).
Without exception, these programmes and community-based in-
terventions have been used repeatedly with male drug-using of-
fenders, but to our knowledge little evidence has been collated
about how these programmes and other available interventions
have been adapted or usedwith female drug-using offenders.Given
that very little is known about what interventions exist for fe-
male drug-using offenders, the focus of this review is to include
all known interventions that have been applied, or specifically
adapted for use with female drug-using offenders. Our only re-
quirement of these programmes is that they are aimed at reducing
drug use or criminal activity, or both.
Why it is important to do this review
Policy interests have also placed an increasing demand on knowing
more about the cost and cost-effectiveness of such interventions.
Some evidence can be drawn from systematic reviews completed
in the area. Despite the growing knowledge of evidence about
the effectiveness of treatment programmes for offenders, in gen-
eral there have been no systematic reviews of treatment outcomes
aimed specifically at drug- using female offenders.
Several reviews have called for additional research on gender dif-
ferences in response to substance use treatment (Plant 2008) and
practice standards (Substance Abuse and Mental Health Services
Administration, SAMHSA 1999), but the outcomes in literature
supporting gender-sensitive treatments in corrections are sparse
(Dolan 2003b; Veysey 2008). Several authors have expressed con-
cerns that substance abuse programmes for women prisoners may
not target the unique needs of incarcerated women or address
their experiences of abuse and victimisation (Mosher 2006). The
evidence suggests that service provision in the USA is low, with
fewer than 1% of correctional agencies offering pharmacotherapy
for their community correctional populations (Taxman 2007).
For these reasons, this updated review provides a systematic exam-
ination of trial evidence relating to the effectiveness of interven-
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tions for female drug-using offenders, given the increasing num-
ber of female offenders who have been incarcerated for substance
misuse problems and drug-related crimes, the lack of knowledge
about how to treat female drug-using offenders, and no previous
systematic review of this question. In order to address this broad
topic, we considered a series of questions to assess the effective-
ness of different interventions, in relation to criminal activity, drug
misuse, treatment setting and type of treatment. The review also
reported descriptively on the costs and cost-effectiveness of such
treatment programmes.
O B J E C T I V E S
To assess the effectiveness of interventions for female drug-using
offenders in reducing criminal activity, or drug use, or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included female drug-using offenders in the review, regard-
less of age or ethnicity. Drug misuse included individuals using
occasional drugs, or who are dependent, or are known to abuse
drugs. Offenders were defined as individuals who were subject to
the criminal justice system. Studies containing male participants
were included in the review only when the trial results reported
the outcomes separately by gender. In these instances we included
only the results for the female participants in the review.
Types of interventions
Included interventions were designed, wholly or in part, to elim-
inate or prevent relapse to drug-use or criminal activity, or both,
among participants. We defined relapse as individuals who may
have returned to an incarcerated setting, or subsequently been ar-
rested, or relapsed into drug misuse. We included a range of dif-
ferent types of interventions in the review.
Experimental interventions included in the review
1. Any pharmacological intervention (e.g. buprenorphine,
methadone).
2. Any psychosocial intervention (e.g. therapeutic community,
case management, cognitive behavioural therapy, interpersonal
psychotherapy, motivational interviewing).
Control Interventions included in the review
1. No treatment.
2. Minimal treatment.
3. Waiting list.
4. Treatment as usual.
5. Other treatment.
Types of outcome measures
Primary outcomes
For the purpose of our review we categorised our primary out-
comes into those relating to dichotomous and continuous drug
use or criminal activity, or both. Where papers reported a number
of different follow-up periods, we reported the longest time pe-
riod, as we felt that such measures provide the most conservative
estimate of effectiveness. For specific meta-analyses of subgroup-
ings, we reviewed all reported follow-up periods to select the most
appropriate time period for combining comparable studies.
1) Drug use measures were reported as:
• self reported drug use (unspecified drug use, specific drug
use not including alcohol, Addiction Severity Index drug
composite scores); and
• biological drug use (measured by drug testing, using either
urine or hair analysis).
2) Criminal activity was measured by:
• self-report or official report of criminal activity, including
arrest for any offence, drug offences, reincarceration,
convictions, charges and recidivism.
Secondary outcomes
Our secondary outcome reported on costs or cost-effectiveness
information. We used a descriptive narrative for these findings.
We undertook a full critical appraisal based on the Drummond
1997 checklist for those studies presenting sufficient information.
Search methods for identification of studies
Electronic searches
The updated searches identified records from 2004 to May 2014.
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• CENTRAL (issue 5, 2014).
• MEDLINE (1966 to May 2014).
• EMBASE (1980 to May 2014).
• PsycINFO (1978 to April 2014).
• Pascal (1973 to November 2004).a
• SciSearch (Science Citation Index) (1974 to April 2014).
• Social SciSearch (Social Science Citation Index) (1972 to
April 2014).
• ASSIA (1987 to April 2014).
• Wilson Applied Science and Technology Abstracts (1983 to
October 2004).a
• Inside Conferences (1993 to November 2004).a
• Dissertation Abstracts (1961 to October 2004).a
• NTIS (1964 to April 2014).
• Sociological Abstracts (1963 to April 2014).
• HMIC (to April 2014).
• PAIS (1972 to April 2014).
• SIGLE (1980 to June 2004).b
• Criminal Justice Abstracts (1968 to April 2014).
• LILACS (2004 to April 2014).
• National Research Register (March 2004).c
• Current Controlled Trials (December 2009).
• Drugscope (February 2004) unable to access.
• SPECTR (March 2004).d
aUnable to access beyond 2004 search.
bDatabase not updated since original 2004 search.
cNo longer exists.
dNow Campbell Collaboration - searched online.
To update the review, we restricted the search strategy to stud-
ies that were published since the end date of the previous search
(March 2013). We did not search a number of original databases
for this update (indicated by the key at the end of the database
list), including Pascal, ASSIA, Wilson Applied Science and Tech-
nology Abstracts, Inside Conferences, and Dissertation Abstracts.
These databases are available only via the fee-charging DIALOG
online host service, and we did not have the resources to undertake
these searches. The National Research Register no longer exists,
and SIGLE has not been updated since 2005. Drugscope is avail-
able only to subscribing members. Drugscope staff undertook the
original searches.
We developed search strategies for each database to exploit the
search engine most effectively and to make use of any controlled
vocabulary. We included methodological search filters designed to
identify RCTs. Whenever possible, we used filters retrieved from
the InterTASC Information Specialists’ Sub-Group (ISSG) Search
Filter Resource site (www.york.ac.uk/inst/crd/intertasc/). If filters
were unavailable from this site, we substituted search terms based
on existing versions.
In addition to the electronic databases, we searched a range of rele-
vant Internet sites:HomeOffice,National Institute ofDrugAbuse
(NIDA), and European Association of Libraries and Information
Services on Alcohol and Other Drugs (ELISAD). We searched
directory Websites, including OMNI (www.omni.ac.uk) up until
November 2011. We did not place any language restrictions on
identification and inclusion of studies in the review.
Details of the updated search strategies and results, and of the
Internet sites searched are listed in Appendix 1; Appendix 2;
Appendix 3; Appendix 4; Appendix 5; Appendix 6; Appendix 7;
Appendix 8; Appendix 9; Appendix 10; Appendix 11; Appendix
12; Appendix 13.
Searching other resources
Reference Checking
We scrutinised the reference lists of all retrieved articles for fur-
ther references, and also undertook searches of the catalogues of
relevant organisations and research founders.
Personal communication
We contacted experts for their knowledge of other studies, pub-
lished or unpublished, relevant to the review.
Data collection and analysis
Selection of studies
Twoauthors independently inspected the search hits by reading the
titles and abstracts, and obtained each potentially relevant study
located in the search as a full-text article in order to independently
assess them for inclusion. In the case of discordance, a third inde-
pendent author arbitrated. One author undertook translation of
articles not written in the English language.
We divided the screening process into two key phases. Phase one
used the initial eight key questions reported in the original review,
as follows.
Prescreening criteria: Phase one
1. Is the document an empirical study? If not, exclude the
document.
2. Does the study evaluate an intervention, a component of
which is designed to reduce, eliminate, or prevent relapse with
drug-using offenders?
3. Are the participants referred by the criminal justice system
at baseline?
4. Does the study report pre- and post-programme measures
of drug use?
5. Does the study report pre- and post-programme measures
of criminal behaviour?
6. Is the study a RCT?
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7. Do the outcome measures refer to the same length of
follow-up for two groups?
After we identified relevant papers from phase one screening, we
sought to identify those papers reporting on outcomes for female
offenders in phase two. We obtained this information primarily
from the participant description in the reporting of the results
section.
Prescreening: Phase two
1. Is the study population composed wholly of female
participants? (If not, then refer to question 2 below).
2. Are the results of the study reported separately by gender?
(If yes, then include the document).
Drug-using interventions were implied if the programme targeted
reduced drug use in a group of individuals. Offenders were indi-
viduals either residing in special hospitals, prisons, the community
(i.e. under the care of the probation service), diverted from court,
or placed on arrest referral schemes for treatment. We included
studies in the review where the entire sample were not drug-us-
ing, but reported pre- and post-measures. The study setting could
change throughout the process of the study, e.g. offenders could
begin in prison but progress through a work release project into
a community setting. Finally, studies need not report both drug
and criminal activity outcomes. If either of these were reported we
included the study in the review.
See Figure 1; Figure 2; Figure 3 for the flow charts of the process
Figure 1. Study flow diagram of paper selection: Original Review
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Figure 2. Study flow diagram of paper selection: First Update
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Figure 3. Study flow diagram and paper selection: Second update
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Data extraction and management
We used data extraction forms to standardise the reporting of
data from all studies obtained as potentially relevant. Two authors
independently extracted data and subsequently checked them for
agreement.
Assessment of risk of bias in included studies
Four authors (AJP, JMG, MMSJ, MJN) independently assessed
risks of bias of all included studies using the ’Risk of bias’ assess-
ment criteria recommended in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011).
The recommended approach for assessing risk of bias in studies
included in a Cochrane review is a two-part process, addressing
seven specific domains, namely sequence generation and alloca-
tion concealment (selection bias), blinding of participants and
providers (performance bias), blinding of outcome assessors (de-
tection bias), incomplete outcome data (attrition bias), selective
outcome reporting (reporting bias), and other potential sources
of bias. The first part of the process involves describing what was
reported to have happened in the study. The second part involves
assigning a judgement relating to the risk of bias for that domain,
in terms of low, high or unclear risk of bias. To make these judge-
ments we used the criteria indicated by theCochrane Handbook for
Systematic Reviews of Interventions adapted to the addiction field.
See Appendix 14 for details.
We addressed the domains of sequence generation and allocation
concealment (avoidance of selection bias) by a single entry for each
study.
We considered blinding of participants, personnel and outcome
assessors (avoidance of performance bias and detection bias) sep-
arately for objective outcomes (e.g. drop out, use of substance
abuse measured by urine analysis, participants relapsed at the end
of follow-up, participants engaged in further treatments), and for
subjective outcomes (e.g. duration and severity of signs and symp-
toms of withdrawal, participants’ self reported use of substance,
side effects, social functioning as integration at school or at work,
family relationships).
We considered incomplete outcome data (avoidance of attrition
bias) for all outcomes except for drop out from the treatment,
which is very often the primary outcome measure in trials of ad-
diction.
For studies identified in the most recent search, we attempted to
contact study authors to establish whether a study protocol was
available.
Measures of treatment effect
We used mean differences (MDs) for outcomes measured on the
same scale and standardised mean differences (SMDs) for out-
comes measured on different scales. Higher scores for continuous
measures are representative of greater harm. We present dichoto-
mous outcomes as risk ratios (RRs), with 95% confidence interval
(CIs).
Unit of analysis issues
To avoid double-counting of outcome measures (e.g. arrest and
parole violation) and follow-up time periods (e.g. 12, 18 months)
we checked all trials to ensure that multiple studies reporting the
same evaluation did not contribute towards multiple estimates of
programme effectiveness. We followed Cochrane guidance and
where appropriate we combined intervention and control groups
to create a single pair-wise comparison. Where this was not ap-
propriate, we selected one treatment arm and excluded the others.
Dealing with missing data
Where we found missing data in the original publication, we at-
tempted to contact the study authors via email to obtain the miss-
ing information.
Assessment of heterogeneity
We assessed heterogeneity using the I² statistic and Chi² statistic
(Higgins 2011).
Data synthesis
We used Review Manager software (RevMan 2014) to perform a
series of meta-analyses for continuous and dichotomous outcome
measures. We used a random-effects model to account for the fact
that participants did not come from a single underlying popula-
tion. The narrative tables include a presentation of the study de-
tails (e.g. author, year of publication, and country of study), study
methods (e.g. random assignment), participants (e.g. number in
sample, age, gender, ethnicity, mental health status), interventions
(e.g. description, duration, intensity and setting), outcomes (e.g.
description, follow-up period and reportingmechanism), resource
and cost information and resource savings (e.g. number of staff,
intervention delivery, estimated costs and estimated savings) and
notes (e.g. methodological and quality assessment information).
For outcomes of criminal activity, there were enough data to allow
us to divide into rearrest and reincarceration.
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Subgroup analysis and investigation of heterogeneity
We planned to conduct a separate subgroup analysis of the studies
by different types of treatments and different settings.
Sensitivity analysis
When appropriate, we had planned to conduct sensitivity analyses
to assess the impact of studies at high risk of bias compared with
those at low or unclear risk. However, because of the overall high
risk of bias of the included studies, we were unable to perform this
analysis.
R E S U L T S
Description of studies
Results of the search
Original review
The original searches spanned from database inception toOctober
2004. This identified a total of 8217 records, and after duplication,
8200. We acquired a total of 90 full-text papers for assessment and
excluded 66 papers, bringing 24 trials to the review (see Figure 1
).
First update
The updated searches spanned from October 2004 until March
2013. This identified a total of 3896 records after duplication. We
acquired a total of 116 full-text papers for assessment and excluded
109 papers, bringing seven new trials to the review (see Figure 2).
Second update
The updated searches spanned fromMarch 2013 until April 2014.
This identified a total of 2092 records after duplication. We ac-
quired a total of 72 full-text papers for assessment and excluded
63 papers, bringing nine trials (represented by 11 publications)
(see Figure 3). See Characteristics of included studies table for full
details.
Included studies
• The nine trials (from 11 publications) included 1792
participants and were published between 1996 and 2014.
Treatment regimes and settings
• Three studies focused on the impact of therapeutic
community programmes in comparison to: i) an alternative
sentencing option; ii) a substance misuse educational cognitive
skills programme; and iii) gender-responsive substance abuse
treatment for women in prison in comparison to standard
therapeutic community programmes (Messina 2010; Nielsen
1996; Sacks 2008).
• Two evaluations of community-based management
(Guydish 2011; Johnson 2011) compared to standard probation
and standard parole supervision, respectively.
• Two studies evaluated: i) a cognitive behavioural
programme versus treatment as usual (Zlotnick 2009); and ii)
combined cognitive behavioural treatment and acceptance and
commitment therapy versus waiting list control (Lanza 2014).
• One study was of a pharmacological intervention in
comparison to a placebo or treatment as usual (Cropsey 2011).
• One study compared interpersonal psychotherapy to an
attention matched psychoeducational control (Johnson 2012).
The studies were categorised by setting, providing three commu-
nity-based studies (Cropsey 2011; Guydish 2011; Johnson 2011)
and six secure-based studies (Johnson 2012; Lanza 2014; Messina
2010; Nielsen 1996; Sacks 2008; Zlotnick 2009).
We identified no studies in a court setting.
Countries in which studies were conducted
Eight studies were set in the USA and one study was conducted
in Spain (Lanza 2014).
Duration of trials
The trial duration varied between three months (Cropsey 2011;
Johnson 2012; Zlotnick 2009) and 18 months (Nielsen 1996).
The majority of studies reported outcomes up to six and twelve
months (Lanza 2014; Guydish 2011; Johnson 2011; Messina
2010; Sacks 2008).
Participants
• The nine studies included adult drug-using women
offenders, with the exception of one study which investigated the
impact of a therapeutic community with adults and young
offenders (Nielsen 1996).
• Two studies also included male offenders (Johnson 2011;
Nielsen 1996), but results for the women were reported
separately, enabling us to extract data specifically for this review.
• The average age of the study participants ranged from a
mean of 31.8 years to 35.6 years.
• In all but one study, the participants were of white ethnic
origin (Nielsen 1996).
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Excluded studies
We excluded a total of 172 studies. See Characteristics of excluded
studies for further details. Reasons for exclusion were: lack of crim-
inal justice involvement in referral to the intervention; not report-
ing relevant drug or crime outcome measures, or both, in both
the pre- and post-intervention periods; and allocation of partici-
pants to study groups that were not strictly randomised or did not
contain original trial data. We excluded the majority of studies
because the study population did not include female participants,
or they were not offenders, or the studies did not report the data
for the female participants separately. We excluded one study be-
cause follow-up periods were not equivalent across study groups
(Di Nitto 2002) and one (Berman 2004) because the intervention
(acupuncture) did not measure our specified outcomes of drug use
or criminal activity. One study reported the protocol of a trial only
(Baldus 2011), while another only contained conference proceed-
ings (Kinlock 2009a).
Risk of bias in included studies
See Figure 4 and Figure 5.
Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 5. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All nine studies were described as randomised. A number of differ-
ent methods were used to perform the random assignment. These
included use of a random number table (Cropsey 2011; Lanza
2014), urn randomisation (Johnson 2011), the use of odd and even
identification numbers (Guydish 2011; Messina 2010), and wave
randomisation (Johnson 2012). The description of the randomi-
sation methodology remained unclear in . For allocation conceal-
ment, two studies noted use of sealed envelopes, (Cropsey 2011;
Guydish 2011), and one study noted concealment from personnel
within the study (Johnson 2012). In the remaining six studies,
no information was reported about allocation concealment and
we therefore rated them as ’unclear’ (Johnson 2011; Lanza 2014;
Messina 2010; Nielsen 1996; Sacks 2008; Zlotnick 2009).
All studies except Nielsen 1996 reported on similar drug use and
criminal behaviour at baseline.
Blinding
We assessed blinding across four dimensions, considering perfor-
mance and detection bias across subjective and objective measures
(see Appendix 14). Reporting of blinding methodology across all
nine studies was not well reported and we judged many studies as
having unclear risk of bias. A handful of studies noted some ele-
ments of blinding across one or more of the four domains. For ex-
ample, Cropsey 2011 considered blinding using a placebo option
but reported concerns about potential contamination which were
difficult to judge. Zlotnick 2009 reported that the outcome asses-
sors were aware of the individual assignment of clients, leading us
to a judgement of high risk for detection bias across all possible
outcome measures. We rated one study at low risk of blinding
across the two measures of outcome blinding, noting that a re-
search assistant was blind at the follow-up assessments after prison
release (Sacks 2008).
Incomplete outcome data
Loss to follow-up was reported in five of the nine studies (Cropsey
2011; Guydish 2011; Johnson 2011; Johnson 2012; Lanza 2014).
Two studies reported adequately on loss to follow-up (Sacks 2008;
Zlotnick 2009). Two studies reported an intention-to-treat anal-
ysis, using the data as participants had been randomised (Messina
2010; Sacks 2008).
Selective reporting
We rated three studies as being at unclear risk of reporting bias
(Cropsey 2011; Johnson 2011; Nielsen 1996), six studies as being
at low risk of selective reporting, and one study as being at high
risk of bias (Johnson 2012).
Other potential sources of bias
Two studies had published a study protocol (Johnson 2011;
Nielsen 1996). Two studies were at unclear risk of other biases
(Cropsey 2011; Messina 2010). We rated four studies at low risk
of other biases (Guydish 2011; Johnson 2011; Lanza 2014; Sacks
2008). We rated the remaining two studies at high risk of bias
as (i) there was a potential for contamination between treatment
and control participants (Zlotnick 2009), and (ii) measurement
of relapse was limited, as nearly a third of the sample remained in
residential treatment at the end of the study (Johnson 2012).
Effects of interventions
See: Summary of findings for the main comparison Any
psychosocial intervention compared to treatment as usual: Drug
use for female drug-using offenders; Summary of findings 2
Any psychosocial intervention compared to treatment as usual for
female drug-using offenders
We included a number of comparisons in a series of meta-analy-
ses (see Table 1) and a ’Summary of findings’ table for the main
comparison (Summary of findings 2). We grouped the studies by
intervention (including any type of psychosocial intervention in
comparison to treatment as usual, and any pharmacological inter-
vention in comparison to a placebo) and outcome type (criminal
activity and drug use). Finally, we considered whether individual
treatment type had an impact on our outcome measures.
1. Any psychosocial intervention versus treatment as
usual
1.1 Drug Use
See Summary of findings for the main comparison
One study (Johnson 2011), did not show a reduction in self re-
ported drug use; 77 participants; RR 0.65, 95% CI 0.20 to 2.12;
low quality of evidence, see Analysis 2.1.
1.2 Arrests
See Summary of findings 2
Two studies (Guydish 2011; Nielsen 1996) did not show a reduc-
tion in rearrest; 489 participants, RR 0.82, (95%CI 0.45 to 1.52);
low quality of evidence See Analysis 1.2.
1.3 Recidivism
See Summary of findings 2
Three studies (Johnson 2011; Nielsen 1996; Zlotnick 2009)
showed a reduction in reincarceration; 630 participants; RR 0.46,
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95% CI 0.34 to 0.64; moderate quality of evidence, see Analysis
1.3.
2.Pharmacological treatment versus placebo
2.1 Drug use
One study (Cropsey 2011) did not show a reduction in self re-
ported drug use; 36 participants; RR 0.58, 95% CI 0.25 to 1.35;
see Analysis 2.1.
3. Psychosocial Interventions
3.1 Interpersonal therapy versus a psychoeducational
attention matched control
Johnson 2012 compared interpersonal psychotherapy in compar-
ison to a psychoeducational attention matched control for women
suffering from major depression. The findings showed that inter-
personal psychotherapy participants had significantly reduced lev-
els of depression and substance misuse over the attention matched
control.
3.2 Cognitive behavioural therapy in comparison to an
acceptance committment therapy versus a control
Lanza 2014 compared an evaluation of cognitive behavioural ther-
apy in comparison to acceptance committment therapy and a con-
trol group. The study results found higher levels of abstinence in
the acceptance commitment therapy (43.8%) when compared to
the control (18.2%).
3.3 Gender-responsive therapeutic community programme
versus a standard therapeutic community regime
Messina 2010 compared a gender-responsive therapeutic com-
munity programme to those in a standard therapeutic commu-
nity regime. The evaluation showed that gender-responsive treat-
ment had a greater impact on reducing both subsequent drug
use and reincarceration, with gender-responsive treatment partic-
ipants voluntarily remaining in aftercare treatment for longer pe-
riods and being less likely than those in standard therapeutic com-
munity care to be reincarcerated within 12 months of parole.
3.4 Therapeutic community intervention in comparison to a
cognitive behavioural therapy
Sacks 2008 compared women assigned to the therapeutic commu-
nity intervention or standard treatment (referred to in the system
as the Intensive Outpatient Programme (IOP)), or cognitive be-
havioural therapy. At six months the study found that both con-
ditions improved significantly for variables of mental health, sub-
stance use, criminal behaviour, and HIV risk.).
Treatment setting
Too few studies were included in the meta-analyses to make a
subgroup analysis for type of setting meaningful.
Cost and cost-effectiveness
None of the nine studies included any cost information which en-
abled a cost-effectiveness evaluation of the interventions. Some de-
scriptive information was provided by one study (Messina 2010).
The study refers to the implications of the gender-responsive treat-
ment programme and speculatively suggests that it may be more
costly to implement and deliver in comparison to a therapeutic
community environment. However, the authors of the study argue
that although costly, reducing recidivism by delivering appropri-
ate services provides a large benefit to further expenditures in the
criminal justice system, and potentially the child welfare system.
The remaining eight studies do not include cost information. Evi-
dence fromother research suggests that substance abuse treatments
in the community are cost-effective, producing a benefit-cost ratio
of 1.74 to 5.74. These findings obviously depend upon the type of
programme (Belenko 2005), and do not examine specifically the
costs associated with the delivery and outcomes of programmes
for female offenders.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Any psychosocial intervention compared to treatment as usual for female drug-using offenders
Patient or population: Female drug-using offenders
Settings: Community/parole
Intervention: Any psychosocial intervention
Comparison: Treatment as usual
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Treatment as usual Any psychosocial inter-
vention
Arrests
Self report/ official
records
Follow-up: 12-18 months
Study population RR 0.82
(0.45 to 1.52)
489
(2 studies)
⊕⊕©©
low1,2
67 per 100 55 per 100
(30 to 100)
Moderate
61 per 100 50 per 100
(27 to 92)
Re-incarceration (plus
arrested and charged
data)
Self reported
Follow-up: 6-9 months
Study population RR 0.46
(0.34 to 0.64)
630
(3 studies)
⊕⊕⊕©
moderate3
35 per 100 16 per 100
(12 to 23)
Moderate
35 per 100 16 per 100
(12 to 23)
1
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The majority of risk of bias outcomes were marked as unclear in both studies. These included blinding and selective reporting.
2 P <0.05, and I2 = 93% suggesting significant levels of heterogeneity across the studies.
3 The majority of risk of bias outcomes in the three studies were marked as unclear. One study marked three items as high risk of bias,
including blinding and other bias.
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D I S C U S S I O N
Summary of main results
This systematic reviewprovides evidence fromnine trials. The nine
studies were based in the community (three studies) and a secure
setting (seven studies). We identified no studies which evaluated
interventions for female offenders in court settings (e.g. pretrial
diversion schemes or mental health courts). For this reason we do
not know whether such interventions work better in one setting
than another. The studies overall, showed a high degree of statisti-
cal variation requiring a degree of caution in the interpretation of
the magnitude of effect and direction of benefit for treatment out-
comes. Four different types of interventions were classified across
the nine studies: (1) therapeutic community and gender-respon-
sive treatment programmes; (2) case management and cognitive
skills; (3) pharmacological treatments; and (4) interpersonal psy-
chotherapy. Below follows a more detailed description of the study
interventions.
Three trials and four publications reported on the effectiveness of
therapeutic communities. First we refer to the two studies which
used the therapeutic community as the intervention group. In
these studies theContinual Recovery throughEducation andSkills
Training (CREST) work release programme was compared to par-
ticipants in the Delaware conventional work release programme.
The evaluation showed that it is possible to successfully combine
the elements of therapeutic community treatmentwith the goals of
work release (Nielsen 1996). More specifically, for participants at-
tending CREST, increased length of time spent in the programme
was associated with lower relapse and recidivism rates, and those
that graduated from the programme fared better than non-gradu-
ates.
The specifically-adapted gender responsive therapeutic commu-
nity programme for women offenders was evaluated by Sacks and
colleagues. This study compared women assigned to the therapeu-
tic community or standard treatment (referred to in the system
as the Intensive Outpatient Programme), or cognitive behavioural
therapy. This consisted of a cognitive behavioural recovery and re-
lapse prevention curriculum (Sacks 2008). At six months the study
found that both conditions improved significantly on variables of
mental health, substance use, criminal behaviour and HIV risk.
They note that further exploration of each model for different of-
fender groups is required to permit a more precise utility of each
model. The study authors conclude that these preliminary find-
ings suggest the importance of providing gender-specific sensitive
and comprehensive approaches within the correctional system to
respond to the complex substance abuse needs of female offend-
ers (Sacks 2008). The more recent follow-up study investigated
outcomes at 6 months and 12 months. The outcomes followed a
similar pattern with both groups of women benefiting from treat-
ment. The therapeutic community programme was found to be
more beneficial than cognitive behavioural therapy at improving
reincarceration rates and lengthening the amount of time spent in
the community before subsequent reincarceration (Sacks 2012).
The final study in this group of therapeutic community eval-
uations compared a gender-responsive treatment programme to
those in a standard therapeutic community programme. The eval-
uation showed that gender-responsive treatment had a greater im-
pact on reducing both subsequent drug use and reincarceration,
with gender-responsive treatment participants voluntarily remain-
ing in aftercare treatment for longer periods and being less likely
than those in standard therapeutic community care to be reincar-
cerated within 12 months of parole. One of the main differences
between gender-responsive treatment and therapeutic community
programmes was the recognition of trauma. The authors argue
that trauma seemed to impact on a range of other outcomes and
was an important aspect of recovery which needed to be addressed.
The possible reason for this benefit may be due to the overall en-
hanced treatment satisfaction of participants compared with those
in the standard treatment group. This finding is supported by
other qualitative researchwhich showed that women attending the
gender-responsive treatment programme were extremely invested
and satisfied with treatment outcomes, and felt supported by other
group members, which may have increased treatment adherence
and recovery (Calhoun 2009; Messina 2010). Additionally, those
women who stayed in treatment voluntarily remained in aftercare
for a longer period of time. A number of implementation barriers
were presented in the study, including the need for ongoing staff
training, technical assistance and monitoring of adherence to the
study protocol.
Evaluations of case management and standard parole showed dis-
appointing results. The Guydish 2011 probation case manage-
ment study found no differential effect. Women in both groups
were equally likely to be arrested during the one-year follow-up
period. The study authors note that although the results indicated
no advantage for probation case management over standard pro-
bation, this finding is similar to other research showing mixed ef-
fects. In particular Treatment Accountability for Safer Commu-
nities interventions incorporating case management and trials of
case management in drug abuse treatment have shown similar re-
sults (Sorenson 2003). The authors note that one key limitation
of the probation case management was the low-level face-to-face
contact. Although probation case management is designed to be
more engaging than standard probation, only 54% of the pro-
bation case management participants reported face-to-face con-
tact with their manager in the six months after programme entry.
The implications suggest that case management based on reduced
caseloads, specialised probation officer training and efforts to in-
crease contact between probation officer and probationer may not
be effective.
Similarly, use of collaborative behaviouralmanagement techniques
in comparison to standard parole did not significantly reduce rein-
carceration (21% of the collaborative behavioural management
participants versus 29% of the control participants) in the nine-
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month follow-up (Johnson 2011). The study did show a reduc-
tion in monthly primary drug use. This is consistent with past
findings which have indicated that women who engage in prison
substance use treatment programmes have lower drug use rates
than men in the months after release from prison (Pelissier 2003).
Other researchers have highlighted this gender effect, suggesting
that factors predicting aftercare treatment completion, post-treat-
ment drug use and recidivism were slightly different for women
than for men, suggesting the possibility of gender-specific path-
ways to successful community re-entry (Pelissier 2003). This find-
ing is important because it may support the idea that optimal tran-
sitional treatments may differ for men and women, however more
randomised trials of transitional interventions for drug-involved
offenders are required (Taxman 2002). The authors suggest that
any gender differences displayed between men and women should
be revisited to assess what important lessons can be applied for the
successful integration of theory- and gender-responsive treatment.
Some successful elements of treatment seemed to include a recog-
nition of success, an emphasis on consistency and fairness from
within the programme, and a focus on overall life functioning and
support (Johnson 2011).
The study evaluating acceptance committment therapy in com-
parison to traditional cognitive behavioural therapy and a control
group found higher levels of abstinence in the acceptance com-
mitment therapy group (43.8%) when compared to the control
(18.2%). These findings are similar to other studies that have used
acceptance commitment therapy, albeit in non-incarcerated pop-
ulations (Hayes 2004). The authors note the success of acceptance
commitment therapy to the nature of the ’co-joint’ work between
the therapist and client. The aim of which is to increase the flex-
ibility and structure of the therapy, allowing the client to have
greater autonomy over making decisions. In contrast, they argue
that cognitive behavioural therapy is more systematically directed
by the therapist, leaving little scope for responsive change (Lanza
2014).
The final study evaluated in this group of analyses compared the
use of a cognitive skills and cognitive behavioural therapy, referred
to as the Seeking Safety Programme. The study compared seek-
ing safety to the standard prison-based substance abuse treatment,
and found no significant differences between conditions on any
measure in the primary analysis (Zlotnick 2009). This finding is
contrary to other research conducted using the Seeking Safety Pro-
gramme with non-correctional clients in the community (Najavits
2006). The authors note that future research should focus specifi-
cally on whether dosage has an impact on the successful outcome
of seeking safety, with participants randomly assigned to different
lengths of treatment. Further difficulties in the evaluation of the
study led to concerns about adherence to the programme once the
women were released into the community. A series of 12 booster
sessions were offered, but on average women only attended three
sessions. The challenge of programme adherence is commonacross
the criminal justice system, especially with those programmes con-
ducted in the community. Given this context, the authors sug-
gest that perhaps longer treatment during prison and increased
frequency of treatment following release may be helpful. A major
question for future research relates to the development of models
for dealing with simultaneous problems and concurrent mental
health issues (Zlotnick 2009).
Pharmacological interventions using buprenorphine for opioid-
dependent women with a HIV risk found that use of buprenor-
phine in prison and continued into the community was beneficial
in preventing or delaying relapse to opioid use (Cropsey 2011).
The findings of this study add to the growing body of evidence
(which primarily includes men) suggesting that buprenorphine is
comparable with both methadone and methadone maintenance
in other studies ( Kinlock 2008; Lobmaier 2010). The findings
were not sustained post-treatment, with most women relapsing to
active opioid use at the three-month follow-up point. Support for
this conclusion using themeta-analysis data suggests no long-term
significant effect. The study did not measure criminal activity, so
we do not know whether such interventions are likely to reduce
subsequent criminal activity in the future.
Interpersonal psychotherapywas evaluated using a pilot studywith
women suffering from major depression and substance use disor-
der (Johnson 2012). This study is primarily a feasibility study to
assess the applicability of using interpersonal psychotherapy in a
prison environment. Despite being small, it is one of the largest
trials including women with co-occurring substance misuse and
mental health problems. The findings showed that interpersonal
psychotherapy participants had significantly reduced levels of de-
pression and substance misuse over the attention matched con-
trol. The study authors note that the intensity of treatment de-
livered, once released into the community, is key to maintaining
good outcomes. However, they go on to state that women often
experience delays in treatment and service provision on release and
they suggest that alternative service provision such as phone treat-
ment might be helpful in providing a more intensive post-release
treatment, and may form a useful contact in times of crisis.
Overall completeness and applicability of
evidence
The paucity of evidence within the review is covered in three key
areas.
General applicability
The applicability of this evidence is hindered in general by a lack
of trials covering a range of different treatment options for female
offenders with drug misuse problems. All but one trial was con-
ducted in the USA and therefore they have limited external valid-
ity to other criminal justice systems outside of the USA. The cur-
rent evidence suggests that therapeutic community programmes
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and the gender-responsive treatment programmes may have some
effect in reducing reincarceration rates, but we do not know how
such treatments facilitate the rehabilitation of female offenders.
Additionally, we can say nothing about whether such treatments
are effective in reducing drug use and subsequent criminal be-
haviour in court.
Adaptation of programmes for female offenders
Most of the studies described the programmes under evaluation
as ’adapted’ or ’amended’ programmes tailored to the needs of
women, but few studies described how the programmes had been
adapted or what considerations had been taken into account. It
is therefore difficult to draw conclusions about the successful ele-
ments of treatment programmes for female offenders.
Cost information
Cost information within the studies was sparse. This lack of infor-
mation allowed for little comparison of cost-effectiveness between
different types of drug treatment programmes. Additional time
spent in programmes also raises questions about reincarceration
and days until first incarceration, generating important cost-avoid-
ance implications which require further examination. Regular re-
porting of effect sizes would aid calculations for power analysis and
provides estimates of themagnitude of treatment effect needed for
cost-benefit and cost-effectiveness analysis. Specific cost informa-
tion for female offenders would also need to consider, for example,
child welfare systems and costs to the wider family network.
Quality of the evidence
We rated the majority of studies as being at ’unclear’ risk of bias
with poor reporting of information by study authors making it
difficult for the authors of this review to assess the extent of poten-
tial bias within the studies. The main limiting factor was the lack
of reporting evidence which prevented the reviewers frommaking
a clear judgement of bias. Since the imprecision of reporting low-
ers the quality of evidence, we judged the evidence to be of low
quality which means that further research is very likely to have
an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Additional concerns with the
research included attrition bias, the series of pilot trials, and the
limited external generalisability associated with such studies and
contamination effects.
A number of studies posed a threat of attrition bias, with over 50%
rated at high risk of attrition. Five of the nine studies were classified
as pilot studies, using sample sizes of 55 or less. The Cropsey 2011
study identified a sample of 36 women, randomly allocating 27
(15 to the intervention and 12 to the placebo group). They note
that although the potency of buprenorphine for control of opioid
use is clearly demonstrated, a larger sample size may be needed
to detect significant differences between groups on other variables
of interest. The study was limited to three months of treatment,
and future studies should explore the provision of buprenorphine
for longer periods of time, to prolong opioid abstinence and to
prevent associated criminal activity.
TheZlotnick 2009 study used a slightly larger sample of 55women
with post-traumatic stress disorder in an incarcerated setting, com-
paring cognitive behavioural therapy plus treatment as usual to
treatment as usual alone. TheMessina 2010 study called for larger
sample sizes and bigger experimental studies. Similarily, the Lanza
2014 study assigned only 50 participants with complex needs,
they note that future research should include larger samples. The
Johnson 2012 study assigned 19 participants to each arm of the
trial and also had difficulties in measuring relapse rates, as 26% of
the sample remained in residential treatment for the entire follow-
up period.
Other potential biases were presented in the Zlotnick 2009 study,
which noted potential contamination problems between the treat-
ment and control conditions across the prison setting. Offend-
ers from different wings or locations within the prison frequently
mixed or moved locations. Finally, they noted that the facilitators
delivered both the treatment intervention and treatment as usual,
and that an immediate post-assessment was not completed. The
authors argue this could have had an unknown effect on the im-
mediate impact of the intervention.
Overall, we judged quality of evidence as moderate to low for the
main comparison, ’any psychosocial intervention versus treatment
as usual’.
Potential biases in the review process
Besides the limitations already discussed, there are also two limita-
tions in the searchmethodology of the review. Specifically, the orig-
inal review included an additional five fee-paying databases and
one search using DrugScope. In this current update, resources did
not allow such extensive searching. Whilst the electronic database
searches have been updated to May 2014, the Website searching
has only been updated to November 2011. As a result, some lit-
erature may have been missed from this updated version.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Three of the nine trials show a positive trend towards the use of
any psychosocial treatment in comparison to treatment as usual,
showing an overall significant reduction in subsequent reincarcer-
ation, but not arrest or drug use. Pharmacological interventions
in comparison to a placebo did not significantly reduce drug use
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and did not measure criminal activity. Four different treatment
comparisons showed varying results and were not combined due
to differences in the intervention and comparison groups. The
studies overall showed a high degree of heterogeneity for types of
comparisons and outcome measures assessed, which limited the
possibility to pool the data. Descriptions of treatment modali-
ties are required to identify the important elements for treatment
success in drug-using female offenders. More trials are required
to increase the precision of confidence with which we can draw
conclusions about the effectiveness of treatments for female drug-
using offenders.
Implications for research
Specific questions in the research literature identify a number of
different gaps in current research.
1. Future work should consider the most appropriate use of
outcomes and produce some standardisation from which
comparisons can be made across the literature.
2. Researchers should also explore the needs of women
attending such courses (e.g. child care restrictions). Qualitative
research into the experiences of women attending, or starting
and not finishing programmes, could help researchers to learn
important lessons in the design of interventions that are
appropriate for this population.
3. Larger-scale trial evaluations need to include information
about the exact nature of the programme, the content, intensity,
delivery and administration. Specific information about how
programmes are adapted or amended for women will provide
important theoretical gender differences for future treatment
programmes targeting female offenders.
4. Very limited information is provided on the costs and
resources involved in the delivery of such interventions. Specific
cost analyses should take into account the large number of
women who also have children and access other sectors of the
welfare system. Developing a cost-benefit methodology alongside
a trial evaluation would help to generate further information
about the potential financial benefits of such programmes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cropsey 2011
Methods Allocation: random assignment
Randomisation method: random number table - first 9 people put on intervention
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: Sealed envelopes, only opened at end of treatment Double-
blinded. Placebo was used, and was not known to evaluators or dispensers during treat-
ment
Loss to follow-up: Partial - large proportion lost to follow-up
Participants 36 adults
Mean age 31.8 (SD 8.4)
100% Female
89% white
100 drug users
Alcohol use: Yes - percentage not available
54.3% prescribed medication for mental illness
Eligibility criteria: adult women, opioid dependent, interest in treatment for opioid
dependence, no contraindications for buprenorphine, due for release from residential
treatment within month, returning to the community, release to correct area
Interventions Community-based pharmacological intervention vs placebo
(I) buprenorphine (n = 24) vs (C) placebo (n = 12)
(I) group was started on 2 mg of buprenorphine, increased to target dose of 8 mg at
discharge. Only 37.2% reached target dose at discharge. (Doses were lower than standard
induction as participants had been in a controlled environment for some time without
access to opiates). Doses were then titrated up to a maximum of 32 mg per day in the
community as clinically indicated. Participants were assessed weekly for side effects, given
drug testing, and counselled by study physician if using drugs. The treatment course was
12 weeks. The (C) group was given a placebo on the same regimen as the (I) group
Outcomes % injection drug use and % urine opiates at end of treatment and 3 months follow-up
Notes No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk First 9 participants deliberately allocated to
intervention for practical reasons, use of a
random number table
Allocation concealment (selection bias) Low risk Use of sealed envelopes
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Cropsey 2011 (Continued)
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk This trial began as an open-label trial then
became a double-blind trial of participants
and providers on all outcomes. Some con-
cerns about contamination issues with the
placebo group but difficult to assess to what
extent the blinding might have been af-
fected
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk This trial began as an open-label trial then
became a double-blind trial of participants
and providers on all outcomes. Some con-
cerns about contamination issues with the
placebo group but difficult to assess to what
extent the blinding might have been af-
fected
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A total of 8 individualswere not included in
the final analysis following randomisation
Selective reporting (reporting bias) Unclear risk No information reported
Other bias Unclear risk Some concerns about potential contamina-
tion between the groups and awareness that
the placebo group might know they were
not receiving the drug but no clear evidence
upon which to make a decision
Guydish 2011
Methods Allocation: random
Randomisation method: sealed envelopes
Similar on drug use: Yes
Similar on criminal activity: Yes
Blinding methodology: Unknown
Loss to follow-up: Partial
Participants 188 adults
Mean age 34.7 (SD 9.2)
100% Female
57.4% African-American
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Guydish 2011 (Continued)
Addiction Severity Index: 50.5 (intervention) 51.6 (control)
Alcohol use: 7.7% intervention, 5.6% control
Beck Depression Inventory mean: 14.6 (intervention) 14.6 (control)
Eligibility criteria: willing to enter substance use treatment, residents of San Francisco,
18 years of age or older, substance use, involved in the criminal justice system
Excluded if multiple violent episodes, current involvement in drug court, court order to
receive probation case management services, or referral by probation officer directly to
the probation case management programme
Interventions Community case management intervention vs standard probation
(I) Probation case management (n = 92). Smaller caseload for officer to allow more
client contact. Client contact at least twice per month. Officers would attend treatment
planning meetings, make home visits, and accompany the client to important meetings.
Could also refer client to other appropriate agencies. Included therapeutic and advocacy
orientation and counselling
(C) Standard probation (n = 96) including preparation of reports for court, supervision
of offender, enforcement of probation conditions, assistance to offender in accessing
necessary services
Outcomes % participants arrested and mean time to first arrest (from administrative data) during
12 month follow-up period
Addiction Severity Index composite scores, reported as relative risk, at 6 months and 12
months
Beck Depression Inventory
Brief Symptom Inventory
Service utilisation
Notes No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment, using even and odd
numbers drawn from sealed envelopes
Allocation concealment (selection bias) Low risk Use of sealed envelopes containing a ran-
domly-generated number
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
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Guydish 2011 (Continued)
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up rates at each time point did not
differ significantly between the groups. At
12 months 82.6% of the probation case
management and 78.0% of the standard
probation were followed up
Selective reporting (reporting bias) Unclear risk No information reported
Other bias Unclear risk No information reported
Johnson 2011
Methods Allocation: random
Randomisation method: urn randomisation
Similar on drug use: Yes
Similar on criminal activity: Not reported
Blinding methodology: Unknown
Loss to follow-up: Partial
Participants 476 adults (n = 77 women)
Men mean age 34.4 years (SD 8.6); Women mean age 35.6 years (SD 8.5)
82% male
51% black
82% used primary drug in pre-prison 6 months
63% men and 39% women self reported alcohol use during pre-prison 6 months
25% lifetime depression
Eligibility criteria: Inclusion: at least 18 years of age, English speaking, probable drug
dependence immediately prior to incarceration (score of 3 or more on drug screen),
substance use treatment as a mandated or recommended condition of parole, moderate
to high risk of drug use relapse and/or recidivism (score of 7 or more on LCSF)
Exclusion: psychotic symptoms, correctional or supervision conditions that prohibited
participation in the study
Interventions Community collaborative behavioural management intervention vs standard parole su-
pervision
(I) Collaborative behavioural management (n = 221). 12-week intervention based on
premise that reinforcement of desired behaviour is more likely to result in sustained
positive change than punishment of undesired behaviour. Involves treatment sessions
with offender, officer, and substance use counsellor at least once every 2 weeks, plus
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Johnson 2011 (Continued)
further officer/offender contacts
(C) Standard parole supervision (n = 210) including weekly to monthly face-to-face
officer/client contact, and drug testing. Officers were affiliated with a substance abuse
treatment programme. Average 1 - 4 contacts per month
Outcomes % reincarcerated (self reported) at 9-month follow-up
% using primary drug (self reported) during 9-month follow-up
Notes Results given separately for men and women, so women-only results presented in this
review
No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomised using urn ran-
domisation to ensure balance of gender and
other factors”
Allocation concealment (selection bias) Unclear risk No information was provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some attrition and loss is reported in the
sample. 476 were interviewed at baseline
but it is unclear how many were ran-
domised and the number of candidates re-
jected is not reported with reasons for ex-
clusion
Selective reporting (reporting bias) Unclear risk No information reported
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Johnson 2011 (Continued)
Other bias Low risk Protocol referred to in the method section
of the study
Johnson 2012
Methods Allocation: random - wave randomisation
Randomisation method: independently generated randomisation sequence. Exact
methodology unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: Principal investigator blinded to initial allocation, data collectors
blinded throughout study period
Loss to follow-up: none reported
Participants 38 adults
Average age: 35 years (SD 9.2)
100 % female
18% Hispanic, 18% African American
58% cocaine dependence, 24% opiate dependence, 21% marijuana dependence, 21%
sedative/hypnotic dependence
58% Alcohol dependence
100 % Psychiatric history
Criteria used for mental health diagnoses - “MDD as determined by the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I; First et al., 1996a) after at
least 4 weeks of abstinence and prison substance use treatment”
Description of mental health problem - MDD
Eligibility criteria: primary MDD as determined by the Structured Clinical Interview
for DSM-IV Axis I Disorders after at least 4 weeks of abstinence and prison substance
use treatment, minimum 17-item Hamilton Depression Scale score of 18, substance use
disorder onemonth prior to incarceration as determined by the SCID, 10-24 weeks away
from prison release. Women with bipolar disorder & psychotic disorder were excluded
Interventions Prison based non-pharmacological intervention vs attention-matched control condition
(I) Interpersonal psychotherapy (n = 19) vs (C) psycho-education (n = 19)
Intervention group
Intervention participants received manualised 60-75 min group sessions three times per
week for 8 weeks plus pre-group, mid group, and post-group individual sessions in prison
for the treatment of substance misuse and mental health problems. Participants in both
conditions also received 6 weekly post-release individual sessions to help maintain gains
and address crises as women transitioned to the community. Session lengths varied be-
tween 60 and 75 min because of time taken to assemble women within the facilities,
occasional early prison counts, and other facility logistics. In-prison treatment was con-
densed into two months because many incarcerated women serve short sentences (30
days, 60 days, 90 days, 180 days). Group sessions were kept short (60 to 75 min) because
prison providers advised us that incarcerated women would have difficulty tolerating
treatment sessions longer than 60 to 75 min
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Johnson 2012 (Continued)
Control group
Control condition participants received attention-matched manualised in-prison and
post-release psycho-education, which is described as co-occurring mental health and
substance use disorders (PSYCHOED). The psycho-education condition was adapted
from a class on co-occurring disorders for prisoners which had been used at the women’s
facilities in the past, but was not being used at the time of the study. It was designed to be
credible and engaging without focusing on the theorised active ingredients of interper-
sonal psychotherapy (e.g. focus on social support, relationships, life changes, analysis of
communication, and exploration of emotions). The stated purpose of PSYCHOEDwas
to help women become informed and empowered consumers of mental health treatment
services. The 24 in-prison sessions focused on the meaning of dual diagnosis, women’s
experience with dual diagnosis, major depression, bipolar disorder, each of the anxiety
disorders, post-traumatic stress disorder, personality disorders, psychotic disorders, eat-
ing disorders, and self care. Sessions for each disorder described symptoms (including
relevant self report tests), interactions between the disorder and substance use, effects of
the disorder on women in prison (including film clips and written stories), and disorder
specific medication and psychosocial treatment options. When a woman in group had
symptoms of a disorder, the group discussed her treatment options and preferences. The
six post-release sessions focused on women’s symptoms and connection with various
mental health and substance use treatment options in the community. Study treatments
took place in addition to prison treatment as usual. Treatment as usual consisted of prison
residential or day treatment for SUD (typically 16 to 30 hrs per week) for all participants
and prison mental health treatment as usual for most participants
Outcomes Relapse within 3-month follow-up period, defined as using drugs on at least 10% of
non-incarcerated days or any positive breath test/urine drug screen. HRSD scores
Notes Work supported by United States National Institute of Drug Abuse
No declarations of interest are noted by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by person in-
dependent of rest of study. Wave randomi-
sation used with at least 8 weeks between
allocation to avoid contamination across
prison wings
Allocation concealment (selection bias) Low risk Allocation adequately concealed fromprin-
cipal investigator and research assistants.
An individual independent concealed the
assignment of each wave before the study
started. After the intake assessment were
complete the PI unsealed the waves treat-
ment assignment
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Johnson 2012 (Continued)
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
subjective measures
Low risk Adequate blinding throughout study. Re-
search assistants who conducted the follow-
up assessment at 3 months after prison re-
lease were kept blind to the condition
Blinding of outcome assessment (detection
bias)
objective measures
Low risk Adequate blinding throughout study. Re-
search assistants who conducted the follow-
up assessment at 3 months after prison re-
lease were kept blind to the condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk
No loss to follow-up, intention-to-treat
analysis
Selective reporting (reporting bias) High risk Did not report on SCID-1/SCID-II,
Trauma History Questionnaire or TLFB
Other bias High risk Authors note that due to the short time line
and limited outcomes made it was difficult
to assess relapse rates as 26% of the sample
remained in residential treatment at the end
of the study
Lanza 2014
Methods Allocation: Allocation did not seem to be concealed
Randomisation method: randomisation table
Similar on drug use: No differences between the groups for “demographic characteristics”
but not sure if this includes drug use. Between group percentages seem very different
Similar on criminal activity: No differences between the groups for “demographic char-
acteristics” but not sure if this includes criminal activity. Between group percentages
seem very different
Blinding methodology: Participants, investigators and assessors were not blinded
Loss to follow-up: All patients lost to follow-up were reported in study flow diagram,
but the authors do not report if there were between group differences
Participants 50 adults
average age: overall mean 33.2 (SD 7.2) (range: 21-49)
(CBT 35.2 (mean) ACT 31.1 (mean); Control 33.1 (mean))
0% male
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Lanza 2014 (Continued)
NR % white
% drug users: CBT 100%, ACT 83.3%, CONTROL 100%
% Alcohol CBT 0%, ACT 16.7%, CONTROL 100%
% Psychiatric history: 86% had at least one mental disorder
Eligibility criteria:
-met diagnostic criteria for current substance use disorder
-serving sentence of more than 6 months
Interventions CBT n = 13 vs ACT (n = 18) vs Control group (n = 13)
Intervention one:
CBT sessions were held in 16 weekly group sessions lasting 90 minutes led by a trained
therapist. CBT was used to change behaviour through cognitive restructuring where
therapist works with offender to identify thoughts that cause distress and uses cognitive
and behavioural therapy to alter resulting behaviour. After treatment offenders were
assessed by the therapist, and follow-up was conducted at six months. Themain outcome
of the CBT intervention was to increase abstinence from drug use, this was measured an
corroborated by urine analysis testing
Intervention two:
ACT - consisted of 16 weekly group sessions lasting 90minutes led by a trained therapist.
ACT seeks to undermine the grip of the literal verbal content of cognition that provokes
avoidance behaviour and constructs an alternative context in which behaviour aligned
with one’s values is more likely to occur. Sessions involve both experiential and didactic
learning to enable clients to experience and understand the size key ACT processes. ACT
helps offenders to respond to previously avoided events in new ways and uses validation
and empowerment. The ACT therapy was aimed at increasing substance use abstinence
within the prison population. After treatment offenders were assessed by the therapist,
and follow-up was conducted at six months
Control group:
Control group received a mental health assessment and then after 6 months received
treatment. The offenders received a re-educational programme for inmates during the
six months
Outcomes Abstinence: 3 months without drug use, self report, corroborated by urinalysis
Anxiety sensitivity measured by Anxiety Sensitivity Index
Mental disorders measured on MINI International Nueropsychiatric interview
Notes Work supported by Trust for the Promotion of Scientific Applied Research and Tech-
nology in Asturias, Spain
A second publication reporting on the same trial comparing two of the three-armed trial
can be found at: Lanza, P., Menedez, G.A. (2013). Acceptance and commitment therapy
for drug abuse in incarcerated women. Psicothema, 25,3,307-312
No conflict of interest reported by authors
Risk of bias
Bias Authors’ judgement Support for judgement
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Lanza 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Use of random number table noted
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk Participants, investigators and assessors
were not blinded to treatment allocation
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk Participants and personnel were not
blinded to treatments
Blinding of outcome assessment (detection
bias)
subjective measures
Low risk Urinalysis was used to corroborate self re-
ported abstinence
Blinding of outcome assessment (detection
bias)
objective measures
High risk Therapists assessed the participants in their
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similiar loss to follow-up across all three
groups. A total of 9/50 lost (n = 4 for ACT,
n = 3 for CBT and n = 2 for control)
Selective reporting (reporting bias) Low risk All outcome measures reported as expected
Other bias Low risk No other concerns
Messina 2010
Methods Allocation: random assignment
Randomisation method: odd and even numbers
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: partial
Participants 115 women
Age not reported
100% women
48% white
100% drug-using
Alcohol use not reported
79% reported a history of depression, 26% met the criteria for PTSD
Eligibility criteria:Womenwith a history of substance use with between 6 and 24months
left to serve on the sentence
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Interventions (I) Gender-responsive treatment (n = 60)
The GRT model encompasses manualised curricula designed to be relevant to the needs
of drug-dependent women in correctional programs. Each provides a facilitator’s
guide and a participant’s workbook. Both curricula use cognitive-behavioral approaches,
mindfulness meditation, experiential therapies (guided imagery, visualisation, art ther-
apy, movement), psychoeducational, relational, and expressive arts techniques. Helping
Women Recover (Covington 2008b) is a 17- session programme organised into four
modules:
(a) Selfmodule: womendiscoverwhat the “self ” is; learn that addiction can be understood
as a disorder of the self; learn the sources of self esteem; consider the effects of sexism,
racism, and stigma on a sense of self; and learn that recovery
includes the growth of the self;
(b) Relationship module: women explore their roles in their families of origin; discuss
myths and realities about motherhood and their relationships with their mothers; review
relationship histories; and consider how they can build healthy support systems;
(c) Sexuality module: women explore the connections between addiction and sexuality
and discuss body image, sexual identity, sexual abuse, and the fear of sex when sober;
(d) Spirituality module: women are introduced to the concepts of spirituality, prayer, and
meditation. Spirituality deals with transformation, connection, meaning, and wholeness
BeyondTrauma (Covington 2003) consists of 11 sessions focused on three areas: teaching
women what trauma and abuse are, helping them to understand typical reactions to
trauma and abuse, and developing coping skills
(C) Standard TC (n = 55)
Prison-based TC programmes in California are based on the traditional aspects of TC
treatment and include the following: (a) activities that embody positive values that start
a process of socialisation; (b) treatment staff who provide positive role models (and
many are recovering addicts themselves); and (c) an alternative concept of inmates that is
usually much more positive than the prevailing beliefs and attitudes held by correctional
staff. Programming takes place during the week, and participants spend approximately
20 hours per week in treatment. A voluntary aftercare component for graduates from
the prison-based TC programmes provides funding for up to 6 months of continued
treatment (residential or outpatient services) in the community following release to
parole. Typically, gender issues and trauma histories were not addressed in these prison
TC programmes. In addition, both men and women were employed as treatment staff
to facilitate the groups and counsel the women
Outcomes Community-based aftercare participation
Drug use
ASI Severity Index Lite
Psychological well being
Self efficacy
Recidivism
All outcomes measured at 6 and 12 months
Notes No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
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Messina 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Random sequence based on an even and
odd identification number
Allocation concealment (selection bias) Unclear risk No evidence reported with regards to con-
cealment
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was conducted
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Protocol not mentioned, but the study rep-
resents a pilot project
Nielsen 1996
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: no
Similar on criminal activity: no
Blinding methodology: unknown
Loss to follow-up: partial
Participants 689 adults and young offenders (women n = 144)
Age not reported
79.1% male
28.9% white
100% drug-using
Alcohol use not reported
Psychiatric history not reported
Eligibility criteria: offenders with a history of drug use who were eligible for work release
or parole and about to be released from prison
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Interventions Secure establishment-based TC vs routine work release
(I) CREST work-release TC (n = 248) 1 month of orientation followed by 2 months of
primary treatment followed by 3 months of work release. This was intensive given the
nature of the intervention
(C) routine work-release (n = 441)
Duration also 6 months, intensity not reported
Outcomes Drug use (self reported) during the last 6 months at 6-month follow-up
Drug use (self reported) during the last 18 months at 18-months follow-up
Recidivism (arrested and charged) for any offence (self reported) during the last 6months
at 6-month follow-up
Recidivism (arrested and charged) for any offence (self reported) during the last 18
months at 18-months follow-up
Notes Farrell 2000 analysed a subset of this work, examining female offenders
No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No intention-to-treat analysis conducted.
No explanation of the impact of with-
drawals
Selective reporting (reporting bias) Unclear risk Not reported
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Other bias Unclear risk Groups are noted as similar except for type
of crime and primary substance use
Sacks 2008
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: high risk; intention-to-treat noted
Participants Sacks 2008
573 adult women
Mean age 35.6 (SD 7.5)
100% female
47.8% white
99% drug-using
Eligibility criteria: female inmates with at least 6 months remaining until parole with se-
rious substance abuse problems requiring treatment and presenting a minimum/medium
security risk
Sacks 2012 - follow-up study at 6 and 12 months
468 adult females
Average age: 35.1 years (SD 7.9)
100% female
47 % white
26% Hispanic
100 % drug users (as measured by Standardised Offender Assessment score)
Alcohol use: not reported
58% lifetime mental health treatment
Eligibility criteria: female offenders at Denver Women’s Correctional Facility; at least 6
months, but no greater than 24 months, remaining before parole eligibility; Colorado
Department of Corrections Standardised Offender Assessments score of 4 or higher
(indicating substance use disorder severe enough to require treatment); security risk level
allowing participation in programme; consented
Interventions (I) TC programme (n = 257) vs (C) cognitive behavioural intervention (n = 211)
Intervention group
TCs were initially designed for use in community-based residential settings, and the
model has been successfully adapted for inmate populations. Themodel has been further
modified for male inmates with co-occurring serious mental and substance use disorders,
with previous evidence showing positive outcomes for re incarceration, substance use,
and mental health symptoms. The intervention involved a 6-month tenure in separate
residential building with programme activities 4 hours per day, 5 days per week, sup-
plemented by peer-led activities at weekends, and a further 4 hours per day, 5 days per
week working within the prison complex. The programme followed TC principles, with
additional gender specific aspects
Control group
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Sacks 2008 (Continued)
The control programme, based at Colorado Department of Corrections (CDOC) stan-
dard treatment, known in the CDOC system as the Intensive Outpatient Programme
(IOP). This is the standard treatment that CDOC offers to all female offenders who
have been classified as substance abusers. The intervention is designed to address sub-
stance abuse and criminality, with a focus on prevention of relapse and recidivism. The
IOP substance abuse treatment curriculum consists of a 90-hour course, presented in an
educational format (Strategies for Self-Improvement and Change, Wanburg & Milkman,
1998), utilizing a cognitive behavioural format to address underlying issues of substance
use/abuse and criminal behavior. The course is completed within 15 weeks. The women
in IOP can participate in multiple other services facility wide including mental health
assessments
Outcomes Criminal activity, arrest, and drug-related activity (self reported) at 6 and 12 months,
and criminal record data (% incarcerated, mean days to incarceration) at 12 months
post-prison release
Self reported illegal drug use at 6 and 12 months
Notes Work supported by US Department of Health and Human Services (DHHS), National
Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
No declarations of interest are noted by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No informationother than “were randomly
assigned”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of outcome assessment (detection
bias)
subjective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
objective measures
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
High risk No loss to follow-up for reincarceration
outcome but unclear loss to follow-up
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Sacks 2008 (Continued)
for other outcomes. Intention-to treat re-
ported. Differences also noted between
data collected using self report and official
records. Intention-to-treat analysis used to
analyse the outcome measures
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk Protocol noted
Zlotnick 2009
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: adequate
Participants 103 female inmates
Mean age 34.6 (SD 7.9)
100% women
46.7% white
100% drug-using
Alcohol use not reported
Eligibility criteria: female inmates requesting intensive substance abuse treatment
Interventions CBT and standard therapy (n = 27) vs standard therapy (n = 22)
Intervention group - CBT using a Seeking Safety programme plus standard therapy
The primary goals of the intervention include the development of coping skills to help
clients attain safety from both PTSD and SUD. The intervention is present-focused,
abstinence-oriented, and emphasises an empowering, compassionate approach. The in-
tervention is conducted using a group modality for 90 min, typically three times a week
for 6 to 8 weeks while the women were in prison, with three to five women per group.
Standard therapy comprises 180-240 hours of group treatment over 6-8 weeks. After re-
lease from prison, each woman was offered weekly individual 60-min “booster” sessions
for 12 weeks to reinforce material from the group sessions
Control group - Standard therapy
Women in the treatment as usual group (or standard therapy) were enrolled in a substance
use treatment programme in the minimum security wing (approximately 30 hours per
week). Women typically attend this programme for 3 to 6 months, depending on the
length of their sentences. Substance use treatment was abstinence-oriented, focused on
the 12-step model (Alcohol Anonymous, Cocaine Anonymous, Narcotics Anonymous)
, and took place in a psychoeducational large-group format, with weekly individual case
management and drug counselling. To remain in the TAU programme, the women had
to attend all components of the treatment. Psychoeducational groups included attention
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Zlotnick 2009 (Continued)
to women’s health, domestic violence, affect management, relapse prevention, career
exploration, anger management, and parenting, conducted by the same clinicians who
conducted the Seeking Safety treatment. This programme did not offer any treatment
specifically for trauma. Prior to prison release, the women received case management ser-
vices, although this discontinued once the women were released from prison. All women
leaving prison were referred for further substance use treatment. The TAU programme
was similar to other state prison substance use programs in that more than 75% of states
offer programs in TC settings, in day treatment settings, teach relapse prevention, and
offer substance use education
Outcomes Drug use (self reported) and recidivism at 3 months and 6 months post-release
Notes No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported other than ’ran-
dom’
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding formed
part of the trial but lack of information
makes it difficult to make an assessment
Blinding of outcome assessment (detection
bias)
subjective measures
High risk p.328 confirms that the assessors were not
blind and were aware of the assignment
Blinding of outcome assessment (detection
bias)
objective measures
High risk p.328 confirms that the assessors were not
blind and were aware of the assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very low and equally balanced attrition in-
dicated in flow chart
Selective reporting (reporting bias) Unclear risk No information reported
Other bias High risk Potential contamination of treatment and
control reported
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ACT: acceptance commitment therapy
C: control
CBT: cognitive behavioural therapy
I: intervention
LCSF: lifestyle criminality screening form
MDD: major depressive disorder
PTSD: post-traumatic stress disorder
SD: standard deviation
TC: therapeutic community
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alemi 2010 No separate results given for female offenders
Alessi 2011 Not an original RCT. Data are from previous, older studies
Andersson 2014 No intervention aimed at reducing drug use in drug-using offenders
Anglin 1999 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Awgu 2010 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Azbel 2013 No intervention aimed at reducing drug use for drug-using offenders
Baldus 2011 Study protocol only, no further data available as author has since died
Baltieri 2014 No intervention aimed at reducing drug use for drug-using offenders
Barnes 2012 Not drug-using offender programme
Bayanzadeh 2004 No separate data for female offenders
Berman 2004 The intervention was not aimed at reducing drug use in drug-using offenders
Black 2011 Not an offender population
Brady 2010 Not randomised controlled trial
Braithwaite 2005 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Breckenridge 2000 Evaluated a DWI Court for alcoholic offenders, not illicit drug use, did not present separate female offender
information
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Britt 1992 No separate results given for female offenders
Brown 2001 3-arm study in which only 2 arms were randomised: 1 treatment arm and control arm. Results presented as
both treatment arms combined vs control
Brown 2013 No separate results given for female offenders
Burdon 2013 No separate results given for female offenders
Carr 2008 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Carroll 2006 No separate results given for female offenders
Carroll 2011 Not an offender population
Carroll 2012 No separate results given for female offenders
Chandler 2006 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Chaple 2014 No pre- and post-test measures of drug and/or crime
Clair 2013 No data presented on pre- and post-test outcome measures
Cogswell 2011 Paper reports on a psychiatric population, not offenders
Cornish 1997 No separate results given for female offenders
Cosden 2003 No separate results given for female offenders
Cosden 2005 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Coviello 2010 No separate results given for female offenders
Coviello 2012 No separate results given for female offenders
Cox 2013 Not a relevant population of criminal justice offenders
Cropsey 2013 No separate results given for female offenders
Cullen 2011 The intervention was not aimed at reducing drug use in drug-using offenders
Cusack 2010 The intervention was not aimed at reducing drug use in drug-using offenders
D’Amico 2013 No separate results given for female offenders
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Dakof 2010 Study population is mothers of offenders, not offenders themselves
Dana 2013 Not a randomised controlled trial
DeFulio 2013 Not a randomised controlled trial
Dembo 2000 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods. The follow-up periods reported for the different groups were not equivalent
Deschenes 1994 No separate results given for female offenders
Di Nitto 2002 The follow-up periods reported for the different groups were not equivalent
Diamond 2006 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Dolan 2003 No separate results given for female offenders
Dole 1969 No separate results given for female offenders
Dugan 1998 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Evans 2012 Not a randomised controlled trial
Forsberg 2011 No separate results given for female offenders
Freudenberg 2010 No separate results given for female offenders
Friedman 2012 Not a randomised controlled trial
Frost 2013 Not a randomised controlled trial
Gagnon 2010 Not an offender population
Gil 2004 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Gordon 2012 No relevant data all analysis at baseline, no outcomes measured at the post-test time point
Gordon 2013 No relevant data; all analysis secondary data; not a primary empirical study
Gottfredson 2002 No separate results given for female offenders
Grohman 2002 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
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Grommon 2013a No separate results given for female offenders
Grommon 2013b No separate results given for female offenders
Guydish 2014 Not criminal justice population
Haapanen 2002 No separate results given for female offenders
Haasen 2010 Not an offender population
Hanlon 1999 No separate results given for female offenders
Harada 2012 No data specifying pre- and post-test outcome measures using drug and/or crime measures
Harrell 2001 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Henderson 2010 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Henggeler 1991 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Henggeler 1999 No separate results given for female offenders
Henggeler 2002 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Henggeler 2006 No separate results given for female offenders
Henggeler 2012 No separate results given for female offenders
Howells 2002 No separate results given for female offenders
Hser 2011 Unclear if study looks at offender population
Hser 2013 No separate results given for female offenders
Inciardi 2004 Some participants were not randomly selected into the treatment groups
Jain 2011 Paper does not report on an offender population
Jones 2013 No separate results given for female offenders
Jones, 2011 No separate results given for female offenders, reports primarily on an alcoholic not drug population
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Katz 2007 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Kelly 2013 No separate results given for female offenders
Kidorf 2013 Not offender population
King 2014 Not offender population
Kinlock 2005 No separate results given for female offenders
Kinlock 2007 No separate results given for female offenders
Kinlock 2008 No separate results given for female offenders
Kinlock 2009a Conference proceedings only
Kinlock 2009b No separate results given for female offenders
Kok 2013 Not offender population
Law 2012 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Lee 2012 No separate results given for female offenders
Liddle 2011 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Ling 2013 Not offender population
Lobmaier 2010 No separate results given for female offenders
Lobmann 2007 No separate results given for female offenders
Lobmann 2009 No data presented for pre- and post-test outcome measures on either drug and/or crime outcomes
MacDonald 2007 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Magura 2009 No separate results given for female offenders
Marlowe 2003 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Marlowe 2005 No separate results given for female offenders
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Marlowe 2007 Participants randomised to receive treatment were not randomised into the different treatment intervention
arms, but were divided into treatment by level of risk. Not a randomised controlled trial
Marlowe 2008 No separate results given for female offenders
Marsch 2014 Not offender population
Martin 1993 No separate results given for female offenders
Mbilinyi 2011 Participants not recruited through criminal justice system
McKendrick 2007 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
McKenzie 2012 No separate results given for female offenders
Messina 2000 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention. The study did not report relevant drug and/or crime outcome measures
at both the pre- and post-intervention periods
Milloy 2011 Study contains no pre-and post-test data on outcomes of drug and/or crime
Needels 2005 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Nemes 1998 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention. The study did not report relevant drug and/or crime outcome measures
at both the pre- and post-intervention periods
Nemes 1999 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention. The study did not report relevant drug and/or crime outcome measures
at both the pre- and post-intervention periods
Nosyk 2010 Not an offender population
Petersilia 1992 No separate results given for female offenders
Petry 2005 Population not 100% from the criminal justice population
Petry 2011 Not an offender population
Polsky 2010 Not an offender population
Prendergast 2003 No separate results given for female offenders
Prendergast 2008 No separate results given for female offenders
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Prendergast 2009 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Prendergast 2011 No separate results given for female offenders
Proctor 2012 No separate results given for female offenders
Reimer 2011 Not an offender population
Robertson 2006 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Rosengard 2008 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Rossman 1999 No separate results given for female offenders
Rounsaville 2001 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Rowan-Szal 2005 Paper not a population of offenders
Rowan-Szal 2009 Not a randomised controlled trial
Rowe 2007 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Sacks 2004 No separate results given for female offenders
Sacks 2012 No separate results given for female offenders
Sanchez-Hervas 2010 Not an offender population
Schaeffer 2014 No separate results given for female offenders
Schmiege 2009 No data available on pre- and post-test outcomes for drug and/or crime measures
Schwartz 2006 Not an offender population
Shanahan 2004 No separate results for female offenders
Sheard 2009 The study did not report relevant drug and/or crime outcomemeasures at both the pre- and post-intervention
periods
Siegal 1999 Not a randomised controlled trial
Sinha 2003 No separate results given for female offenders
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Smith 2010 No separate results given for female offenders
Solomon 1995 Not an offender population
Specka 2013 Not an offender population
Stanger 2009 The population of the study was not 100% drug using offenders that were specifically referred by the criminal
justice system to the intervention
Staton-Tindall 2009 No control group; not a randomised controlled trial
Stein 2006 No data available for pre- and post test outcomes on drug and/or crime outcomes
Stein 2010 Not an offender population
Stein 2011 No separate results given for female offenders
Stevens 1998 The study did not include an appropriate comparison group. The population of the study was not 100%
drug-using offenders that were specifically referred by the criminal justice system to the intervention
Svikis 2011 Not clear if offender population
Taxman 2006 No separate results given for female offenders
Vagenas 2014 No pre- and post-test outcomes for drug and/or crime measures
Vanderberg 2002 No pre- and post-test outcomes for drug and/or crime measures
Walters 2014 No pre- and post-test outcomes for drug and/or crime measures
Wang 2010 Participants not in criminal justice system
Webster 2014 No pre- and post-test outcomes for drug and/or crime measures
White 2006 Randomisation broken as 40% of control arm were allowed to receive treatment (acupuncture) outside of
the intervention
Williams 2011 Not randomised controlled trial
Winstanley 2011 Not an offender population
Witkiewitz 2010 Not an offender population
Wolff 2012 No data for pre- and post-test outcomes of drug and/or crime measures
Wright 2011 No separate results given for female offenders
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Characteristics of ongoing studies [ordered by study ID]
Springer 2015
Trial name or title Naltrexone for opioid dependent released HIV+ criminal justice populations
Referred to as NEWHOPE
Methods Our specific aim is to conduct a placebo-controlled RCT of depot NTX (d-NTX) for HIV+ prisoners with
OD who are transitioning to the community
150 subjects within CJS in NewHaven, Hartford and Springfield. Subjects will be randomised 2:1 to d-NTX
or d-placebo for 6 months and observed for 12 months
Participants HIV-infected prisoners with opioid dependence who are treated with depot- naltrexone as they are transi-
tioning from the correctional to the community setting
150 participants
Interventions Depot naltrexone versus placebo
Outcomes 6 and 12 months
HIV treatment (HIV-1 RNA levels, CD4 count, ART adherence, retention in care), substance abuse (time to
relapse to opioid use, % opioid negative urine, opioid craving), adverse side effects and HIV risk behaviour
(sexual and drug-related risks)
The public health relevance is that outcomes from this study will establish the efficacy, safety and tolerability of
pharmacological therapy using naltrexone treatment among HIV+S and establish depot-naltrexone treatment
as an effective, evidence-based treatment for opioid dependence for released HIV+ prisoners
Starting date 2012
Contact information Yale University
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Any psychosocial intervention versus treatment as usual: criminal activity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self reported drug use
dichotmous
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Arrests 2 489 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.45, 1.52]
3 Recidivism (reincarceration,
arrested and charged)
3 630 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.34, 0.64]
Comparison 2. Pharmacological interventions versus placebo: drug use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self reported drug use 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Any psychosocial intervention versus treatment as usual: criminal activity,
Outcome 1 Self reported drug use dichotmous.
Review: Interventions for female drug-using offenders
Comparison: 1 Any psychosocial intervention versus treatment as usual: criminal activity
Outcome: 1 Self reported drug use dichotmous
Study or subgroup Any Psyccosocial Treat as usual Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 2011 4/39 6/38 0.65 [ 0.20, 2.12 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (Any Psyccosocial), 6 (Treat as usual)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours any psychosocial Favours treat as usual
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Analysis 1.2. Comparison 1 Any psychosocial intervention versus treatment as usual: criminal activity,
Outcome 2 Arrests.
Review: Interventions for female drug-using offenders
Comparison: 1 Any psychosocial intervention versus treatment as usual: criminal activity
Outcome: 2 Arrests
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Guydish 2011 60/92 53/91 50.2 % 1.12 [ 0.89, 1.41 ]
Nielsen 1996 55/144 102/162 49.8 % 0.61 [ 0.48, 0.77 ]
Total (95% CI) 236 253 100.0 % 0.82 [ 0.45, 1.52 ]
Total events: 115 (Experimental), 155 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 13.59, df = 1 (P = 0.00023); I2 =93%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours any psychosocial Favours treat as usual
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Analysis 1.3. Comparison 1 Any psychosocial intervention versus treatment as usual: criminal activity,
Outcome 3 Recidivism (reincarceration, arrested and charged).
Review: Interventions for female drug-using offenders
Comparison: 1 Any psychosocial intervention versus treatment as usual: criminal activity
Outcome: 3 Recidivism (reincarceration, arrested and charged)
Study or subgroup any psychosocial treatment as usual Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 2011 8/39 11/38 15.9 % 0.71 [ 0.32, 1.57 ]
Nielsen 1996 28/190 113/319 72.2 % 0.42 [ 0.29, 0.60 ]
Zlotnick 2009 5/23 9/21 11.9 % 0.51 [ 0.20, 1.27 ]
Total (95% CI) 252 378 100.0 % 0.46 [ 0.34, 0.64 ]
Total events: 41 (any psychosocial), 133 (treatment as usual)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.76 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours any psychosocial Favours treat as usual
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Analysis 2.1. Comparison 2 Pharmacological interventions versus placebo: drug use, Outcome 1 Self
reported drug use.
Review: Interventions for female drug-using offenders
Comparison: 2 Pharmacological interventions versus placebo: drug use
Outcome: 1 Self reported drug use
Study or subgroup pharmacological int placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cropsey 2011 7/24 6/12 0.58 [ 0.25, 1.35 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (pharmacological int), 6 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacoological Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Summary comparison data for meta-analyses
Paper, year Intervention Comparison Follow-up Outcome type Measurement Actual outcome
Cropsey 2011 Buprenorphine Placebo End of treatment
3 months
Bi-
ological drug use
(dichotomous);
self re-
ported drug use
(dichotomous)
% with total % positive urine
opiates
%
self reported in-
jection drug use
Guydish 2011 Case
management
Standard proba-
tion
12 months Criminal activity
(continuous);
criminal activity
(dichotomous)
Mean and SD
% with total
Mean arrests
during follow-up
(official)
% arrested dur-
ing follow-uppe-
riod (official)
Johnson 2011
(women)
Collabora-
tive behavioural
management
Standard parole
supervision
9 months Criminal activity
(dichotomous);
self re-
ported drug use
(dichotomous)
% with total % women rein-
carcerated
% women used
primary drug
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Table 1. Summary comparison data for meta-analyses (Continued)
Johnson 2012 Interpersonal
Psychotherapy
Attention-
matched control
condition
3 months Self re-
ported drug use
(dichotomous)
% with total Relapse within 3
months follow-
up period, de-
fined as using
drugs on at least
10% of non-in-
carcerated days
or any positive
breath test/urine
drug screen
Lanza 2014 Accep-
tance and com-
mitment therapy
and cognitive be-
havioural
therapy
Control group 6 months Self reported
drug use (di-
chotomous); bi-
ological drug use
(dichotomous)
% with total Abstinence:
3 months with-
out drug use, self
report, corrobo-
rated by urinaly-
sis
Messina 2010 Gender-respon-
sive Treatment
Standard Thera-
peutic Commu-
nity
6 months
12 months
Criminal activity
(dichotomous
and continuous)
;
self reported
drug use
% with total Com-
munity-based af-
tercare Participa-
tion
Drug use
ASI Lite
Psychological
well being
Self efficacy
Recidivism
Nielsen 1996 Therapeutic
community
Routine work re-
lease
6 months
18 months
Criminal activity
(dichotomous);
self re-
ported drug use
(dichotomous)
% and total % recidivism
% relapse
Sacks 2008 Ther-
apeutic commu-
nity and cogni-
tive skills train-
ing.
Sub-
stance abuse ed-
ucation and cog-
nitive skills ther-
apy
6 months
12 months
Criminal activity
(dichotomous);
self re-
ported drug use
(dichotomous
and continuous)
% and total % arrested for
any offence
% arrested (not
parole violation)
%criminal activ-
ity
% drug-related
crime self report
% incarcerated
andmean days to
incarceration
Illegal drug use
% sex crime
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Table 1. Summary comparison data for meta-analyses (Continued)
Mean highest
frequency drug
use
% drug use
% received sub-
stance abuse
treatment in 6
months follow-
ing programme
Zlotnick 2009 Cogni-
tive behavioural
therapy
Treatment as
usual
3 months
6 months
Criminal activity
(dichotomous);
self reported
druguse (contin-
uous)
% and total % return to
prison
Mean ASI (drug)
composite score
Self reported
weeks abstinent
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE search
1. exp “Substance-Related-Disorders”/
2. ((drug or substance) adj (abuse* or addict* or dependen* or misuse*)).ti,ab
3. (drug* adj (treat* or intervention* or program*)
4. substance near (treat* or intervention* or program*)
5.(detox* or methadone) in ti,ab
6. narcotic* near (treat* or intervention* or program*)
7. 1 or 2 or 3 or 4 or 5 or 6
8. prison*. ti,ab
9. exp “Prisoners”/
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(Continued)
10. offender* or criminal* or inmate* or convict* or probation* or remand or felon*).ti,ab
11. exp “Prisons”/
12. 8 or 9 or 10 or 11
13. 7 and 12
Appendix 2. EMBASE search strategy
EMBASE search
1. (detox$ or methadone or antagonist prescri$).ti,ab.
2. detoxification/ or drug detoxification/ or drug withdrawal/ or drug dependence treatment/ or methadone/ ormethadone treatment/
or diamorphine/ or naltrexone/
3. (diamorphine or naltrexone or therapeutic communit$).ti,ab
4. morality/
5. (motivational interview$ or motivational enhancement).ti,ab
6. (counselling or counseling).ti,ab.
7. exp counseling/
8. (psychotherap$ or cognitive behavioral or cognitive behavioural).ti,ab
9. exp psychotherapy/
10. (moral adj3 training).ti,ab.
11. (cognitive restructuring or assertiveness training).ti,ab
12. reinforcement/ or self monitoring/ or self control/
13. (relaxation training or rational emotive or family relationship therap$).ti,ab
14. social learning/ or withdrawal syndrome/ or coping behavior/
15. (community reinforcement or self monitoring or self control or self management or interpersonal skills).ti,ab
16. (goal$ adj3 setting).ti,ab.
68Interventions for female drug-using offenders (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
17. (social skills adj3 training).ti,ab.
18. anger/ or lifestyle/
19. (basic skills adj3 training).ti,ab.
20. (relapse adj3 prevent$).ti,ab.
21. (craving adj3 (minimi$ or reduc$)).ti,ab.
22. (trigger or triggers or coping skills or anger management or group work).ti,ab
23. (lifestyle adj3 modifi$).ti,ab.
24. (high intensity training or resettlement or throughcare or aftercare or after care).ti,ab
25. aftercare/ or halfway house/
26. (brief solution or brief intervention$ or minnesota program$ or 12 step$ or twelve step$).ti,ab
27. (needle exchange or nes or syringe exchange or dual diagnosis or narcotics anonymous).ti,ab
28. self help/ or support group/
29. (self-help or selfhelp or self help or outreach or bail support or arrest referral$).ti,ab
30. exp urinalysis/ or rehabilitation/ or rehabilitation center/
31. (diversion or dtto or dttos or drug treatment or testing order$ or carat or carats).ti,ab
32. (combined orders or drug-free or drug free).ti,ab.
33. (peer support or evaluation$ or urinalysis or drug testing or drug test or drug tests).ti,ab
34. ((rehab or rehabilitation or residential or discrete) adj2 (service$ or program$)).ti,ab
35. (asro or addressing substance$ or pasro or prisons addressing or acupuncture or shock or boot camp or boot camps).ti,ab
36. (work ethic camp$ or drug education or tasc or treatment accountability).ti,ab
37. exp acupuncture/
38. or/1-36
39. (remand or prison or prisoner or prisoners or offender$ or criminal$ or probation or court or courts).ti,ab
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(Continued)
40. (secure establishment$ or secure facilit$).ti,ab.
41. (reoffend$ or reincarcerat$ or recidivi$ or ex-offender$ or jail or jails or goal or goals).ti,ab
42. (incarcerat$ or convict or convicts or convicted or felon or felons or conviction$ or revocation or inmate$ or high security).ti,ab
43. criminal justice/ or custody/ or detention/ or prison/ or prisoner/ or offender/ or probation/ or court/ or recidivism/ or crime/ or
criminal behavior/ or punishment/
44. or/39-43
45. 38 and 44
46. (substance abuse$ or substance misuse$ or substance use$).ti,ab
47. (drug dependanc$ or drug abuse$ or drug use$ or drug misuse$ or drug addict$).ti,ab
48. (narcotics adj3 (addict$ or use$ or misuse$ or abuse$)).ti,ab
49. (chemical dependanc$ or opiates or heroin or crack or cocaine or amphetamines or addiction or dependance disorder or drug
involved).ti,ab
50. substance abuse/ or drug abuse/ or analgesic agent abuse/ or drug abuse pattern/ or drug misuse/ or intravenous drug abuse/ or
multiple drug abuse/
51. addiction/ or drug dependence/ or narcotic dependence/ or exp narcotic agent/ or narcotic analgesic agent/
52. opiate addiction/ or heroin dependence/ or morphine addiction/
53. cocaine/ or amphetamine derivative/ or psychotropic agent/
54. or/46-53
55. 45 and 54
Appendix 3. PsycInfo search strategy
PsycInfo
1. (detoxification in de) or (drug withdrawal in de)
2. (drug usage screening in de) or (methadone maintenance) in de
3. explode “Narcotic-Antagonists” in DE
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(Continued)
4. 1 or 2 or 3
5. (counseling in de) or (explode “psychotherapeutic-counseling” in de)
6. (explode “cognitive-therapy” in de) or (explode “psychotherapeutic-techniques” in de)
7. (cognitive restructuring in de) or (assertiveness training in de)
8. explode “relaxation-therapy” in de
9. (rational emotive therapy in de) or (rational-emotive therapy in de)
10. (explode “self monitoring” in de) or (explode self-monitoring) in de
11. (goal setting in de) or (self control in de) or (explode “self-management” in de)
12. (social skills in de) or (relapse prevention in de) or (craving in de) or (coping behavior in de)
13. (anger control in de) or (explode “group-psychotherapy” in de) or (brief psychotherapy in de)
14. (explode “behavior-modification” in de) or (posttreatment followup in de) or (aftercare in de)
15. (halfway houses in de) or (twelve step programs in de)
16. (dual diagnoses in de) or (explode “self help techniques” in de) or (outreach programs in de) or (court referrals in de)
17. (peer pressure in de) or (urinalysis in de)
18. (drug rehabilitation in de) or (residential care institutions in de) or (acupuncture in de) or (drug education in de)
19. (detox* or methadone or antagonist prescri* or diamorphine or naltrexone or therapeutic communit*) in ti,ab
20. (motivational interview* or motivational enhancemen* or counseling or psychotherapy or psychotherapies) in ti,ab
21. (cognitive behav* or cognitive therapy or cognitive therapies or moral training or cognitive restructuring) in ti,ab
22. (assertiveness training or relaxation training or relaxation therapy or relaxation therapies) in ti,ab
23. (rational emotive therap* or rational emotive behav* therap* or family relationship therap* or community reinforcement) in ti,ab
24. (self-monitor* or self monitor* or goal setting or self control or self-control or self management or self-management) in ti,ab
25. (interpersonal skills training or social skills training or basic skills training) in ti,ab
26. (relapse with prevent*) in ti,ab
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(Continued)
27. (craving near reduc*) in ti,ab
28. craving with (reduc* in ti,ab)
29. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement) in ti,
ab
30. (throughcare or aftercare or after care or brief solution* or brief intervention*) in ti,ab
31. (minnesota or 12 step* or twelve step* or needle exchange or nes or syringe exchange or dual diagnosis) in ti,ab
32. (narcotics anonymous or self-help or self help or outreach or bail support or arrest referral*) in ti,ab
33. (diversion or dtto* or testing order* or carat* or counseling assessment referral or combined order or combined orders or drug
free wing* or drug free environment*) in ti,ab
34. (peer support or user evaluations or urinalysis or urinalyses or mandatory drug test* or rehabilitation or discrete service* or discrete
program*) in ti,ab
35. (residential program* or residential scheme* or asro or addressing substance* or pasro or prisons addressing substance) in ti,ab
36. (acupuncture or shock or boot camp* or work ethic or drug education or tasc or treatment accountability) in ti,ab
37. or/4-36
38. (secure facilities or convict* or revocation or inmate* or high security) in ti,ab
39. (prisoners in de) or (explode “correctional-institutions” in de)
40. (perpetrators in de) or (explode criminals in de)
41. (probation in de) or (parole in de) or (incarceration in de) or (recidivism in de) or (criminal conviction in de) or (crime in de)
42. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment* or reoffend* or reincarcerat*
or recidivi* or ex-offender* or jail or jails or incarcerat*) in ti,ab
43. (drug abuse in de) or (explode “inhalant-abuse” in de) or (explode “drug-dependency” in de)
44. (polydrug abuse in de) or (drug abuse in de) or (intravenous drug usage in de)
45. (narcotic drugs in de) or (heroin in de) or (cocaine in de) or (explode amphetamine in de)
46. (substance abuse* or substance misuse* or substance user*) in ti,ab
47. (drug dependen* or drug abuse* or drug misuse* or drug addict* or drug use) in ti,ab
48. (narcotic abuse* or narcotic misuse* or chemical dependen* or opiate misuse* or opiate abuse*) in ti,ab
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(Continued)
49. (heroin use* or heroin addict* or heroin misuse* or heroin abuse*) in ti,ab
50. (crack use* or crack addict* or crack misuse* or crack abuse*) in ti,ab
51. (cocaine use* or cocaine addict* or cocaine misuse* or cocaine abuse*) in ti,ab
52. (amphetamine* use* or amphetamine* addict* or amphetamine* misuse* or amphetamine* abuse*) in ti,ab
53. (dependence disorder or drug involved or dug-involved) in ti,ab
54. #38 or #39 or #40 or #41 or #42
55. #4 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53
56. #37 and #54 and #55
Appendix 4. SPECTRA search strategy
SPECTRA search
1. {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
{remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
2. {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict}
All indexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or
{secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
OR
All unindexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment}
or {secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
AND
All unindexed fields: {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict} or {narcotics} or {opiates}
or {heroin} or {crack} or {cocaine} or {amphetamines} or {drug involved} or {substance-related} or {amphetamine-related} or {cocaine-
related} or {marijuana} or {opioid} or {street drug} or {designer drug}
3. narcotics
4. opiates
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(Continued)
5. heroin
6. {crack}
7. cocaine
8. amphetamines
9. drug involved
10. substance-related
11. amphetamine-related
12. cocaine-related
13. marijuana
14. opioid
15. street drug
16. designer drug
17. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 1 AND 17
Appendix 5. PASCAL. SciSearch, Social SciSSciSearch, Wilson Applied Science and Technology
Abstracts search strategy
PASCAL search
1. (DETOX? OR METHADONE OR ANTAGONIST()PRESCRI?)/TI,AB
2. METHADONE/DE OR NALTREXONE/DE
3. (DIAMORPHINE OR NALTREXONE)/TI,AB
4. THERAPEUTIC()COMMUNITY/DE OR THERAPEUTIC()COMMUNIT?)/TI,AB
5. (MOTIVATIONAL()INTERVIEW? ORMOTIVATIONAL()ENHANCEMENT)/TI,AB
6. (COUNSELLING OR COUNSELING)/TI,AB
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(Continued)
7. COUNSELING/DE
8. (PSYCHOTHERAP? OR COGNITIVE()BEHAVIORAL OR COGNITIVE()BEHAVIOURAL)/TI,AB
9. PSYCHOTHERAPY!/DE
10. (MORAL(3W)TRAINING)/TI,AB
11. (COGNITIVE()RESTRUCTURING OR ASSERTIVENESS()TRAINING)/TI,AB
12. ASSERTIVENESS/DE OR RELAXATION()TECHNIQUES/DE
13. (RELAXATION()TRAINING OR RATIONAL()EMOTIVE OR FAMILY()RELATIONSHIP()THERAP?)/TI,AB
14. FAMILY()RELATIONS/DE
15. (COMMUNITY()REINFORCEMENT OR SELF()MONITORING OR SELF()CONTROL OR SELF()MANAGEMENT
OR INTERPERSONAL()SKILLS)/TI,AB
16. (GOAL?(3W)SETTING)/TI,AB
17. (SOCIAL(3W)TRAINING)/TI,AB
18. SOCIAL RESPONSIBILITY/DE
19. (BASIC()SKILLS(3W)TRAINING)/TI,AB
20. (RELAPSE(3W)PREVENT?)/TI,AB
21. (CRAVING(3W)(MINIMI? OR REDUC?))/TI,AB
22. (TRIGGER OR TRIGGERS OR COPING()SKILLS OR ANGER()MANAGEMENT OR GROUP()WORK)/TI,AB
23. (LIFESTYLE(3W)MODIFI?)/TI,AB
24. (HIGH()INTENSITY()TRAININGORRESETTLEMENTORTHROUGHCARE ORAFTERCAREORAFTER()CARE)
/TI,AB
25. ADAPTATION,-PSYCHOLOGICAL!/DE OR ANGER/DE OR LIFE()STYLE/DE OR AFTER()CARE/DE ORHALFWAY
()HOUSES/DE
26. (BRIEF()SOLUTION OR BRIEF()INTERVENTION? OR MINNESOTA()PROGRAM? OR 12()STEP? OR TWELVE()
STEP?)/TI,AB
27. (NEEDLE()EXCHANGE OR NES OR SYRINGE()EXCHANGE OR DUAL()DIAGNOSIS OR NARCOTICS()ANONY-
MOUS)/TI,AB
28. NEEDLE-EXCHANGE()PROGRAMS/DE
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(Continued)
29. (SELF-HELP OR SELFHELP OR SELF()HELP OR OUTREACH OR BAIL()SUPPORT OR ARREST()REFERRAL?)/TI,
AB
30. SELF-HELP()GROUPS/DE OR URINALYSIS/DE OR SUBSTANCE()ABUSE()DETECTION/DE
31. (DIVERSION ORDTTO ORDTTOS ORDRUG()TREATMENT OR TESTING()ORDER? ? OR CARAT OR CARATS)
/TI,AB
32. (COMBINED()ORDERS OR DRUG-FREE OR DRUG()FREE)/TI,AB
33. (PEER()SUPPORT OR EVALUATION? ? OR URINALYSIS OR DRUG()TESTING OR DRUG()TEST? ?)/TI,AB
34. ((REHAB OR REHABILITATION OR RESIDENTIAL OR DISCRETE)(2W)(SERVICE? ? OR PROGRAM?))/TI,AB
35. (ASROORADDRESSING()SUBSTANCE?ORPASROORPRISONS()ADDRESSINGORACUPUNCTUREORSHOCK
OR BOOT()CAMP OR BOOT()CAMPS)/TI,AB
36. (WORK()ETHIC()CAMP? ? OR DRUG()EDUCATION OR TASC OR TREATMENT()ACCOUNTABILITY)/TI,AB
37. ACUPUNCTURE-THERAPY!/DE OR ACUPUNCTURE/DE OR HEALTH()EDUCATION/DE OR SUBSTANCE()
ABUSE()TREATMENT()CENTERS/DE
38. S1:S3
39. S4:S37
40. S38 AND S39
40. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER? ? OR CRIMINAL? ? OR PROBATION OR
COURT OR COURTS)/TI,AB
41. (SECURE()ESTABLISHMENT? ? OR SECURE()FACILIT?)/TI,AB
42. (REOFFEND? OR REINCARCERAT? OR RECIDIVI? OR EX()OFFENDER? ? OR JAIL OR JAILS)/TI,AB
43. (INCARCERAT? OR CONVICT OR CONVICTS OR CONVICTED OR FELON? ? OR CONVICTION? ? OR REVO-
CATION OR INMATE? ? OR HIGH()SECURITY)/TI,AB
44. PRISONERS/DE OR LAW()ENFORCEMENT/DE OR JURISPRUDENCE/DE
45. S40:S44
46. S40 AND S45
47. (SUBSTANCE()ABUSE? OR SUBSTANCE()MISUSE? OR SUBSTANCE()USE?)/TI,AB
48. (DRUG()DEPENDANC? OR DRUG()ABUSE? OR DRUG()USE? OR DRUG()MISUSE? OR DRUG()ADDICT?)/TI,AB
49. (NARCOTICS(3W)(ADDICT? OR USE? OR MISUSE? OR ABUSE?))/TI,AB
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50. (CHEMICAL()DEPENDANC? OR OPIATES OR HEROIN OR CRACK OR COCAINE OR AMPHETAMINES OR
ADDICTION OR DEPENDENCE()DISORDER OR DRUG()INVOLVED)/TI,AB
51. SUBSTANCE-RELATED()DISORDERS/DE OR AMPHETAMINE-RELATED()DISORDERS/DE OR COCAINE-RE-
LATED()DISORDERS/DE OR MARIJUANA ()ABUSE/DE
52. OPIOID-RELATED-DISORDERS!/DE OR PHENCYCLIDINE()ABUSE/DE OR SUBSTANCE()ABUSE()INTRA-
VENOUS/DE
53. STREET()DRUGS/DE OR DESIGNER()DRUGS/DE OR NARCOTICS/DE
54. COCAINE!/DE OR AMPHETAMINES!/DE OR ANALGESICS()OPIOID/DE
55. S47:S54
56. S46 AND S55
57. (DETOXIFICATION OR METHADONE OR ANTAGONIST-PRESCRIBING)/DE FROM 144,34,434,7,99,65,35,6
58. (DIAMORPHINE OR NALTREXONE)/DE FROM 144,34,434,7,99,65,35,6
59. THERAPEUTIC-COMMUNITY)/DE FROM 144,34,434,7,99,65,35,6
60. (MOTIVATIONAL-INTERVIEW OR MOTIVATIONAL-ENHANCEMENT)/DE FROM 144,34,434,7,99,65,35,6
61. (COUNSELLING OR COUNSELING)/DE FROM 144,34,434,7,99,65,35,6
62. (PSYCHOTHERAPY! OR COGNITIVE-BEHAVIORAL OR COGNITIVE-BEHAVIOURAL)/DE FROM 144,34,434,7,
99,65,35,6
63. (MORAL-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
64. (COGNITIVE-RESTRUCTURING OR ASSERTIVENESS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
65. (RELAXATION-TRAINING OR RATIONAL-EMOTIVE OR FAMILY-RELATIONSHIP-THERAPY)/DE FROM 144,34,
434,7,99,65,35,6
66. FAMILY-RELATIONS/DE
67. (COMMUNITY-REINFORCEMENT OR SELF-MONITORING OR SELF-CONTROL OR SELF-MANAGEMENTOR
INTERPERSONAL-SKILLS)/DE FROM 44,34,434,7,99,65,35,6
68. (GOAL-SETTING)/DE FROM 144,34,434,7,99,65,35,6
69. (SOCIAL-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
70. SOCIAL-RESPONSIBILITY/DE
71. (BASIC-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
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72. (RELAPSE-PREVENTION)/DE FROM 144,34,434,7,99,65,35,6
73. CRAVING/DE FROM 144,34,434,7,99,65,35,6
74. (TRIGGER OR COPING-SKILLS OR ANGER-MANAGEMENT OR GROUP-WORK)/DE FROM 144,34,434,7,99,65,
35,6
75. (LIFESTYLE-MODIFICATION)/DE FROM 144,34,434,7,99,65,35,6
76. (HIGH-INTENSITY-TRAINING OR RESETTLEMENT OR THROUGHCARE OR AFTERCARE OR AFTER-CARE)/
DE FROM 144,34,434,7,99,65,35,6
77. (BRIEF-SOLUTION OR BRIEF-INTERVENTIONS OR MINNESOTA-PROGRAM OR 12-STEP-PROGRAM OR
TWELVE-STEP-PROGRAM)/DE FROM 144,34,434,7,99,65,35,6
77. (NEEDLE-EXCHANGE OR SYRINGE-EXCHANGE OR DUAL-DIAGNOSIS OR NARCOTICS-ANONYMOUS)/DE
FROM 144,34,434,7,99,65,35,6
79. (SELF-HELP OR OUTREACH OR BAIL-SUPPORT OR ARREST-REFERRAL)/DE FROM 144,34,434,7,99,65,35,6
80. (DRUG-TREATMENT OR TESTING-ORDERS OR CARAT)/DE FROM 144,34,434,7,99,65,35,6
81. (COMBINED-ORDERS OR DRUG-FREE)/DE FROM 144,34,434,7,99,65,35,6
82. (PEER-SUPPORT OR EVALUATION OR URINALYSIS OR DRUG-TESTING OR DRUG-TESTS)/DE FROM 144,34,
434,7,99,65,35,6
83. (REHABILITATION OR RESIDENTIAL OR DISCRETE-SERVICES)/DE FROM 144,34,434,7,99,65,35,6
84. (ASRO OR PASRO ACUPUNCTURE OR BOOT-CAMP)/DE FROM 144,34,434,7,99,65,35,6
85. (WORK-ETHIC-CAMP OR DRUG-EDUCATION OR TASC OR TREATMENT-ACCOUNTABILITY)/DE FROM 144,
34,434,7,99,65,35,6
86. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER OR OFFENDERS OR CRIMINAL OR
CRIMINALS OR PROBATION OR COURT OR COURTS)/DE FROM 144,34,434,7,99,65,35,6
87. (SECURE-ESTABLISHMENTS OR SECURE-FACILITY)/DE FROM 144,34,434,7,99,65,35,6
88. (REOFFENDERS OR REINCARCERATION OR RECIDIVISM OR EX-OFFENDERS OR JAILS)/DE FROM 144,34,
434,7,99,65,35,6
89. (INCARCERATIONORCONVICTORCONVICTSORFELONORFELONSORCONVICTIONSORREVOCATION
OR INMATE OR INMATES OR HIGH-SECURITY)/DE FROM 144,34,434,7,99,65,35,6
90. (SUBSTANCE-ABUSE OR SUBSTANCE-MISUSE OR SUBSTANCE-USE)/DE FROM 144,34,434,7,99,65,35,6
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91. (DRUG-DEPENDANCEORDRUG-DEPENDENCYORDRUG-ABUSEORDRUG-MISUSEORDRUG-ADDICT OR
DRUG-ADDICTION)/DE FROM 144,34,434,7,99,65,35,6
92. (CHEMICAL-DEPENDANCY OR OPIATE-DEPENDENCY OR HEROIN-DEPENDENCY OR CRACK-DEPEN-
DENCY OR COCAINE-DEPENDENCY OR AMPHETAMINES OR ADDICTION OR DEPENDENCE-DISORDER OR
DRUG-INVOLVED)/DE FROM 144,34,434,7,99,65,35,6
93. S40 OR S57:S85
94. S45 OR S86:S89
95. S55 OR S90:S92
96. S93 AND S94 AND S95
97. S96/1980-2004
Appendix 6. The CENTRAL Register of Controlled trials search strategy
CENTRAL search
1. prison*
2. offender*
3. (criminal* or probation or court*)
4. (secure next establishment*)
5. reoffend*
6. reincarcerat*
7. recidiv*
8. exoffend*
9. (jail or jails or incarcerat*)
10. (secure next facilit*)
10(secure next facilit*)
11. (convict* or revocation or inmate* or (high next security))
12. PRISONERS
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13. LAW ENFORCEMENT
14. JURISPRUDENCE
15. CRIME
16. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
17. SUBSTANCE-RELATED DISORDERS
18. ((substance or drug*) next (abuse* or misuse* or dependen*or use* or addict*))
19. (narcotics or chemical or opiate) next (dependen* or addict* or abuse* or misuse*))
20. ((heroin) next (addict* or dependen* or misuse* or abuse*))
21. ((crack) next (addict* or dependen* or misuse* or abuse* or use*))
22. ((cocaine next addict*) or (cocaine next dependenc*) or (cocaine next misuse*) or (cocaine next abuse*) or (cocaine next use*))
23. ((amphetamine*) next (addict* or dependen* or misuse* or abuse* or use*))
24. (addicts or (dependence next disorder) or (drug next involved))
25. (street next drugs)
26. STREET DRUGS
27. DESIGNER DRUGS
28. NARCOTICS
29. COCAINE
30. AMPHETAMINES
31. ANALGESICS ADDICTIVE
32. ANALGESICS OPIOID
33. PSYCHOTROPIC DRUGS
34. opioid* or opiat*
35. #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
35. (#16 and #35)
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SIGLE
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab
5. ((substance abuse* or substance misuse* or substance use*) in ti,ab
6. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
7. ((dependence disorder or drug involved) in ti,ab
8. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
9. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
10. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
11. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
12. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
13. #1 or #2
14. #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
15. #13 and #14
Appendix 8. Sociological Abstracts search strategy
Sociological Abstracts
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
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5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
12. criminal proceedings in de
13. recidivism in de
14. jail in de
15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
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29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
36. #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
37. #19 and #36
38. “Detoxification-” in DE
39. “Methadone-Maintenance” in DE
40. “Counseling-” in DE
41. “Psychotherapy-” in DE
42. “Assertiveness-” in DE
43. (detoxification in de) or (methadone maintenance in de) or (treatment programs in de)
44. (counseling in de) or (psychotherapy in de) or (assertiveness in de) or (group therapy in de) or (goals in de) or (self control in de)
45. (interpersonal communication in de) or (social interaction in de) or (social competence in de) or (coping in de)
46. (social behavior in de) or (group work in de) or (lifestyle in de)
47. (after care in de) or (support networks in de) or (self help in de) or (self help groups in de) or (outreach programmes in de)
48. (outreach programs in de) or (referral in de) or (delinquency prevention in de) or (diversion/diversions in de)
49. (peer groups in de) or (peer influence in de) or (drug use screening in de) or (rehabilitation in de) or (work experience in de)
50. (detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
51. (therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab
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52. (moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab
53. (rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal setting
or self control training) in ti,ab
54. (self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab
55. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab
56. (aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle exchange
or nes) in ti,ab
57. (syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab
58. (arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders) in
ti,ab
59. (drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab
60. (residential program* or residential scheme* or residential service*) in ti,ab
61. (asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab
62. (work ethic or drug education or tasc or treatment accountability) in ti,ab
63. #38 or #39 #or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #
55 or #56 or #57 or #58 or #59 or #60 or #61 or #62
64. #37 and #63
Appendix 9. ASSIA search strategy
ASSIA search
1. remand
2. prison or prisoner or prisoners
3. offender*
4. criminal*
84Interventions for female drug-using offenders (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
5. probation
6. court or courts
7. tribunal or tribunals
8. secure establishment*
9. secure facilit*
10. reoffend*
11. reincarcerat*
12. recidivi*
13. ex-offender*
14. jail or jails
15. incarcerat*
16. convict or convicts
17. convicted
18. felon or felons
19. conviction*
20. reconviction*
21. high security
22. law enforcement
23. Substance abuse* or substance misuse* or substance use*
24. drug dependanc* or drug abuse* or drug use*
25. drug misuse* or drug addict*
26. narcotics addict* narcotics use* narcotics misuse* narcotics abuse*
27. chemical dependanc*
28. opiates
29. heroin
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30. crack
31. cocaine
32. amphetamines
33. cocaine
34. addiction
35. dependence disorder*
36. drug involved
37. Substance-related disorders
38. amphetamine-related disorders
39. cocaine-related disorders
40. marijuana abuse
41. opioid-related disorders
42. street drugs
43. designer drugs
44. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
45. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
46. 44 and 45
Appendix 10. HMIC search strategy
HMIC
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
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5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
12. criminal proceedings in de
13. recidivism in de
14. jail in de
15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
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29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
36. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
37. #19 and #36
Appendix 11. National Research Register search strategy
NRR search
1. REMAND
2. PRISON*
3. OFFENDER*
4. ((CRIMINAL* or PROBATION) or COURT) or COURTS)
5. (SECURE next ESTABLISHMENT*)
6. REOFFEND*
7. REINCARCERAT*
8. RECIDIV*
9. EXOFFEND*
10. ((JAIL or JAILS) or INCARCERAT*)
11. (SECURE next FACILIT*)
12. (((CONVICT* or REVOCATION) or INMATE*) OR (HIGH next SECURITY))
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13. PRISONERS:ME
14. LAW-ENFORCEMENT:ME
15. JURISPRUDENCE:ME
16. CRIME:ME
17. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
18. #11 or #12 or #13 or #14 or #15 or #16
19. #17 or #18
20. ((SUBSTANCE next ABUSE*) or (SUBSTANCE next MISUSE*)) OR (DRUG NEXTDEPENDENC*)) OR (DRUG NEXT
ABUSE*)) OR (DRUG NEXT MISUSE*)) OR (DRUG NEXT USE*)) OR (DRUG NEXT ADDICTION))
21. ((NARCOTICS or (CHEMICAL next DEPENDENC*)) OR (OPIATE NEXT ADDICT*)) OR (OPIATE NEXT DEPEN-
DENC*)) OR (OPIATE NEXT ABUSE*)) OR (OPIATE NEXT MISUSE*))
22. ((HEROIN next ADDICT*) or (HEROIN next DEPENDENC*)) OR (HEROIN NEXT MISUSE*)) OR (HEROIN NEXT
ABUSE*))
23. ((CRACK next ADDICT*) or (CRACK next DEPENDENC*)) OR (CRACK NEXT MISUSE*)) OR (CRACK NEXT
ABUSE*)) OR (CRACK NEXT USE*))
24. ((COCAINE next ADDICT*) or (COCAINE next DEPENDENC*)) OR (COCAINE NEXT MISUSE*)) OR (COCAINE
NEXT ABUSE*)) OR (COCAINE NEXT USE*))
25. ((AMPHETAMINE* next ADDICT*) or (AMPHETAMINE* next DEPENDENC*)) OR (AMPHETAMINE* NEXT MIS-
USE*)) OR (AMPHETAMINE* NEXT ABUSE*)) OR (AMPHETAMINE* NEXT USE*))
26. ((ADDICTS or (DEPENDENCE next DISORDER)) OR (DRUG NEXT INVOLVED))
27. (SUBSTANCE-RELATED and DISORDERS:ME)
28. SUBSTANCE-RELATED-DISORDERS:ME
29. AMPHETAMINE-ABUSE:ME
30. COCAINE-ABUSE:ME
31. MARIJUANA-ABUSE:ME
32. OPIOID-RELATED-DISORDERS:ME
33. PHENCYCLIDINE-ABUSE:ME
34. SUBSTANCE-ABUSE-INTRAVENOUS:ME
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35. SUBSTANCE-WITHDRAWAL-SYNDROME:ME
36. (STREET next DRUGS)
38. STREET-DRUGS:ME
39. DESIGNER-DRUGS:ME
40. NARCOTICS:ME
41. (COCAINE:ME or AMPHETAMINES:ME)
42. ANALGESICS-ADDICTIVE:ME
43. ANALGESICS-OPIOID:ME
44. PSYCHOTROPIC-DRUGS:ME
45. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37
or #38 or #39 or #40 or #41 or #42 or #43 or #44
46. 19 and 45
Appendix 12. PAIS search strategy
PAIS
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab)
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab)
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab) or ((substance abuse* or substance misuse* or substance use*) in ti,ab)
5. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab)
6. ((dependence disorder or drug involved) in ti,ab)
7. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab)
8. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab)
9. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab)
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10. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab)
11. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab)
12. ((moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab)
13. ((therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab)
14. ((work ethic or drug education or tasc or treatment accountability) in ti,ab)
15. ((asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab)
16. ((arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders)
in ti,ab)
17. ((residential program* or residential scheme* or residential service*) in ti,ab)
18. ((syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab)
19. ((drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab)
20. ((aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle
exchange or nes) in ti,ab)
21. ((trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab)
22. ((self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab)
24. ((rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal
setting or self control training) in ti,ab)
25. #1 or #2
26. #3 or #4 or #5 or #6 or #7 or #8 or 9 or #10 or #11
27. #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
28. 25 and #26 and #27
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Appendix 13. Criminal Justice Abstracts search strategy
CJA search
1. (substance abuse* or substance misuse* or substance use or substance users) in ti,ab,de
2. substance related in ti,ab,de
3. drug related in ti,ab,de
4. (drug dependenc* or drug abuse* or drug misuse* or drug use or drug users or drug addiction) in ti,ab,de
5. (narcotics use or narcotics users or narcotics abuse* or narcotics misuse* or chemical dependenc*) in ti,ab,de
6. (opiates or heroin or crack or cocaine or amphetamines or addict or addicts or addicted or dependence disorder* or drug involved)
in ti,ab,de
7. (designer drugs or street drugs or polydrug misuse* or polydrug abuse*) in ti,ab,de
8. #1 or #2 or #3 or #4 or #5 or #6 or #7
9. ((antagonist near prescri*) or diamorphine or naltrexone) in ti,ab,de
10(therapeutic communit* or (motivational near interview*)) in ti,ab,de
11. (motivational near enhancement) in ti,ab,de
12. (counselling or counseling) in ti,ab,de
13. (psychotherap* or cognitive behav* or behav* therap* or (moral near training)) in ti,ab,de
14. (cognitive restructuring or (assertiveness near train*) or relaxation training) in ti,ab,de
15. (rational emotive or family relationship therap*) in ti,ab,de
16. (community reinforcement or self monitoring or goal setting or goalsetting) in ti,ab,de
17. (self control near training) in ti,ab,de
18. (self management) in ti,ab,de
19. (interpersonal skills near training) in ti,ab,de
20. ((social skills or basic skills) near training) in ti,ab,de
21. ((relapse near prevent*) or (craving near reduc*)) in ti,ab,de
22. (trigger* or coping skills or anger management or group work or (lifestyle near modif*)) in ti,ab,de
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23. (high intensity training or resettlement or throughcare or aftercare or after care) in ti,ab,de
24. (brief solution* or brief intervention*) in ti,ab,de
25. (minnesota in ti,ab) in ti,ab,de
26. (12 step* or twelve step*) in ti,ab,de
27. (needle exchange or nes or syringe exchange) in ti,ab,de
28. (dual diagnosis or narcotics anonymous or self help or selfhelp or outreach) in ti,ab,de
29. (bail support or bail program* or arrest referral* or diversion or dtto* or drug treatment) in ti,ab,de
30. (carat or counselling assessment or counseling assessment) in ti,ab,de
31. (combined order* or drug free wing* or drug free environment* or peer support) in ti,ab,de
32. (user evaluations or urinalys* or urinanalys* or drug test* or rehab* or discrete service*) in ti,ab,de
33. (discrete program* or residential program* or residential scheme*) in ti,ab,de
34. (asro or addressing substance*) in ti,ab,de
35. (pasro or prisons addressing) in ti,ab,de
36. (acupuncture or shock or boot camp or boot camps or work ethic camp*) in ti,ab,de
37. (drug education or tasc or treatment accountability) in ti,ab,de
38. (detoxification or detox or methadone maintenance or (methadone near prescri*)) in ti,ab,de
39. #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
or #27 or #28 or #29
40. #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
41. #39 or #40
42. #8 and #41
9. #42 and (PY > “1979”)
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Appendix 14. Criteria for ’Risk of bias’ assessment
Item Judgement Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal al-
location: central allocation (including telephone, web-based, and phar-
macy-controlled randomisation); sequentially numbered drug contain-
ers of identical appearance; sequentially numbered, opaque, sealed en-
velopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or non opaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias):
objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding; blinding
of participants and key study personnel ensured, and unlikely that the
blinding could have been broken
4. Blinding of participants and providers
(performance bias):
subjective outcomes
Low risk Blinding of participants and providers and unlikely that the blinding
could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
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(Continued)
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
5. Blinding of outcome assessor (detection
bias):
objective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
6.Blinding of outcome assessor (detection
bias):
subjective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding; blinding of outcome assess-
ment, but likely that the blinding could have been broken, and the out-
come measurement is likely to be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
7. Incomplete outcome data (attrition bias)
for all outcomes except retention in treat-
ment or drop out
Low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically relevant
impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans or
standardised difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods;
All randomised participants are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention-to-treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation;
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(Continued)
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop out not reported for each group)
8. Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s prespecified (primary
and secondary) outcomes that are of interest in the review have been
reported in the prespecified way;
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were prespecified
(convincing text of this nature may be uncommon)
High risk Not all of the study’s prespecified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not prespecified;
One or more reported primary outcomes were not prespecified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One ormore outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgement of low or high risk
9. Other bias Low risk Evidence to suggest other problems identifiedwith the studywhichmight
threaten the validity of the random allocation, attrition or data integrity
and results of the trial
High risk Evidence to suggest that the trial might be underpowered/problems with
the random allocation process leading to potential self selection bias/
issues of analysis not conducted using intention-to-treat analysis or evi-
dence of missing data. Concerns of attrition and measurement error in-
cluding reliance on self reported measures
Unclear risk Insufficient information to permit judgement of low or high risk
WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2014.
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Date Event Description
18 May 2015 New citation required and conclusions have changed Conclusions quite different for some outcomes
11 July 2014 New search has been performed This update represents an additional three trials; bringing
the total number of trials in this review to nine. The search
strategies are complete up until May 2014
H I S T O R Y
Review first published: Issue 1, 2014
Date Event Description
24 January 2014 Amended Plain language summary title correction
28 May 2013 New search has been performed This review has been updated using searches to 21st
March 2013. The review represents one in a family of four
reviews. The other three reviews cover pharmacological
and non- pharmacological interventions for drug using
offenders and interventions for drug-using offenders with
co-occurring mental illness. This review on drug-using
female offenders concerns a total of 11 new randomised
controlled trials, representing 1236 participants
2 March 2012 New search has been performed The updated edit of this review produced a new docu-
ment with additional findings with searches up to 11th
November 2011. Five new authors have been added to
this version of the review. These include Steven Duffy,
Rachael McCool, Matthew Neilson, Catherine Hewitt
and Marrissa Martyn-St James
1 July 2011 Amended Converted to new review format
8 June 2011 New search has been performed Review has been substantially updated
19 May 2006 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
Searches were constructed and conducted by DF. Three independent review authors inspected the search hits by reading the titles and
abstracts (AEP, MN, RW). Each potentially relevant study located in the search was obtained as a full article and was independently
assessed for inclusion by two review authors. In the case of discordance, a third independent review author arbitrated. Where it was
not possible to evaluate the study because of language problems or missing information, the studies were classified as ’translation/
information required to determine decision’ until a translation or further details were provided. Four review authors conducted data
extraction for the papers (MM-ST, JMG, RW, and MN), and review author CG conducted data extraction and a narrative summary
of the cost-effectiveness studies. The results were compiled and organised by MM-ST, MN, CH, RW, and AEP; all seven authors
contributed towards the final draft text.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original review Perry 2006 has been split up into different reviews and so there is no dedicated protocol for this particular review
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Buprenorphine [therapeutic use]; Case Management; Cognitive Therapy; Criminals; Law Enforcement; Narcotic Antagonists [thera-
peutic use]; Randomized Controlled Trials as Topic; Sex Factors; Substance-Related Disorders [∗therapy]; Therapeutic Community
MeSH check words
Female; Humans
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